<SEC-DOCUMENT>0001558370-16-003734.txt : 20160301
<SEC-HEADER>0001558370-16-003734.hdr.sgml : 20160301
<ACCEPTANCE-DATETIME>20160301160125
ACCESSION NUMBER:		0001558370-16-003734
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20160301
DATE AS OF CHANGE:		20160301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-202808
		FILM NUMBER:		161473155

	BUSINESS ADDRESS:	
		STREET 1:		401 PROFESSIONAL DRIVE, SUITE 250
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
		BUSINESS PHONE:		240-243-1201

	MAIL ADDRESS:	
		STREET 1:		401 PROFESSIONAL DRIVE, SUITE 250
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>glyc-20160301x424.htm
<TEXT>
<!--HTML document created with Merrill Bridge  6.1.177.0-->
<!--Created on: 3/1/2016 11:51:41 AM-->
<html>
	<head>
		<title>
			glyc_Current_Folio_ProSupp
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;text-align:right;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<a name="_GoBack"></a><font style="display:inline;font-weight:bold;font-size:10pt;">Filed pursuant to Rule 424(b)(5) </font>
		</p>
		<p style="margin:0pt;text-align:right;border-top:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Registration No.&nbsp;333-202808 </font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:left;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">PROSPECTUS</font><font style="display:inline;font-weight:bold;"> SUPPLEMENT</font><br /><font style="display:inline;font-weight:bold;">(to Prospectus dated March 24, 2015)</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"><img src="glyc20160301xs3001.jpg" style="width: 1.885417in; height: 0.3645833in" alt="Picture 5"></font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">$</font><font style="display:inline;font-weight:bold;">19</font><font style="display:inline;font-weight:bold;">,000,000</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Common Stock</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="center"></hr></div>
		<p style="margin:0pt;line-height:10pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">We have entered into a certain Sales Agreement, or </font><font style="display:inline;color:#000000;">the </font><font style="display:inline;color:#000000;">sales agreement, with Cowen and Company, LLC, or Cowen, relating to shares of our common stock offered by this prospectus</font><font style="display:inline;color:#000000;"> supplement</font><font style="display:inline;color:#000000;">. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having an aggr</font><font style="display:inline;color:#000000;">egate offering price of up to $</font><font style="display:inline;color:#000000;">40.0</font><font style="display:inline;color:#000000;"> million</font><font style="display:inline;color:#000000;"> from time to time through Cowen.</font><font style="display:inline;color:#000000;"> This prospectus supplement is only offering $19.0 million in shares of our common stock. We will be required to file another prospectus supplement in the event we want to offer more than $19.0 million in shares of our common stock in accordance with the sales agreement.</font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our common stock is traded on the N</font><font style="display:inline;">ASDAQ</font><font style="display:inline;"> Global Market</font><font style="display:inline;">, or </font><font style="display:inline;">the </font><font style="display:inline;">Exchange,</font><font style="display:inline;"> under the symbol &#x201C;</font><font style="display:inline;">GLYC</font><font style="display:inline;">.&#x201D; On </font><font style="display:inline;">February 29</font><font style="display:inline;">, 201</font><font style="display:inline;">6</font><font style="display:inline;">, the last reported sale</font><font style="display:inline;"> price of our common stock was $</font><font style="display:inline;">4.54</font><font style="display:inline;font-weight:bold;">&nbsp;</font><font style="display:inline;">per share.</font><font style="display:inline;font-weight:bold;">&nbsp;</font><font style="display:inline;color:#000000;background-color: #FFFFFF;">Pursuant to</font><font style="display:inline;color:#000000;background-color: #FFFFFF;"> General Instruction I.B.6 </font><font style="display:inline;color:#000000;background-color: #FFFFFF;">of Form S-3, in no event will we sell securities registered on the registration statement of which this prospectus is a part in a public primary offering with a value exceeding more than one-third of our public float in any 12-month period if our public float, measured in accordance with such instruction, remains below $75.0 million. As of the date hereof, we have not offered any securities pursuant to</font><font style="display:inline;color:#000000;background-color: #FFFFFF;"> General Instruction I.B.6 </font><font style="display:inline;color:#000000;background-color: #FFFFFF;">of Form S-3 during the 12 calendar months prior to and including the date of this prospectus supplement.</font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">Sales of our common stock, if any, under this prospectus </font><font style="display:inline;color:#000000;">supplement </font><font style="display:inline;color:#000000;">may be made in sales deemed to be &#x201C;at-the-market&#x201D; equity offerings as defined in Rule&nbsp;415 promulgated under the Securities Act of 1933, as amended, or the Securities Act, including sales made directly on or through the Exchange, the existing trading market for our common stock, sales made to or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, and/or any other method permitted by law. Cowen is not required to sell any specific number or dollar amount of securities, but will act as a sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Cowen and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.</font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">The compensation to Cowen for sales of common stock sold pursuant to the sales agreement will be an amount </font><font style="display:inline;color:#000000;">equal</font><font style="display:inline;color:#000000;"> to </font><font style="display:inline;">3</font><font style="display:inline;color:#000000;">% of the gross proceeds of any shares of common stock sold under the sales agreement. In connection with the sale of the common stock on our behalf, Cowen will be deemed to be an &#x201C;underwriter&#x201D; within the meaning of the Securities Act and the compensation of Cowen will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Cowen with respect to certain liabilities, including liabilities under the Securities Act or the Exchange Act of 1934, as amended, or the Exchange Act.</font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="center"></hr></div>
		<p style="margin:0pt;text-indent:0pt;text-align:left;border-top:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#x201C;Risk Factors&#x201D; </font><font style="display:inline;font-weight:bold;">on page </font><font style="display:inline;font-weight:bold;">S-</font><font style="display:inline;font-weight:bold;">5</font><font style="display:inline;font-weight:bold;">&nbsp;</font><font style="display:inline;font-weight:bold;">of this prospectus supplement</font><font style="display:inline;font-weight:bold;"> and under similar headings in the other documents that are incorporated by reference into this prospectus</font><font style="display:inline;font-weight:bold;"> supplement</font><font style="display:inline;font-weight:bold;">. &nbsp;</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="center"></hr></div>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;text-indent:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS</font><font style="display:inline;font-weight:bold;"> SUPPLEMENT AND THE ACCOMPANYING PROSPECTUS</font><font style="display:inline;font-weight:bold;">&nbsp;</font><font style="display:inline;font-weight:bold;">ARE</font><font style="display:inline;font-weight:bold;"> TRUTHFUL OR COMPLETE.&nbsp;&nbsp;ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</font><font style="display:inline;font-weight:bold;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;line-height:10pt;text-indent:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1.5pt solid #000000 ;border-top:1pt none #D9D9D9 ;text-indent:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Cowen and Company</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1.5pt solid #000000 ;text-indent:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">The date of this prospectus</font><font style="display:inline;font-weight:bold;"> supplement</font><font style="display:inline;font-weight:bold;"> is</font><font style="display:inline;font-weight:bold;">&nbsp;</font><font style="display:inline;font-weight:bold;">March </font><font style="display:inline;font-weight:bold;">1</font><font style="display:inline;font-weight:bold;">, 2016</font><font style="display:inline;font-weight:bold;">.</font><a name="TOC"></a><font style="display:inline;font-weight:bold;color:#000000;"></font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:center;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;line-height:10pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;background-color: #FFFFFF;text-align:center;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-weight:bold;">TABLE OF CONTENTS</font>
		</p>
		<p style="margin:8.15pt 0pt 0pt;background-color: #FFFFFF;text-align:center;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">Prospectus </font><font style="display:inline;font-weight:bold;color:#000000;">Supplement</font>
		</p>
		<p style="margin:4.5pt 0pt 0pt 432pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;text-align:justify;text-justify:inter-ideograph;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:91.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">2</font></p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-bottom:1pt none #D9D9D9 ;width:06.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:91.78%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.16%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Page</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:91.78%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ABOUT_310985"><font style="display:inline;">ABOUT THIS PROSPECTUS SUPPLEMENT</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.16%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">i</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:91.78%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#PROSPECTUS_783439"><font style="display:inline;">PROSPECTUS SUPPLEMENT SUMMARY</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.16%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">S-</font>1<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:91.78%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#THE_804524"><font style="display:inline;">THE OFFERING</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.16%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">S-</font>4<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:91.78%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#RISK_367046"><font style="display:inline;">RISK FACTORS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.16%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">S-</font>5<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:91.78%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#SPECIALNOTE_124015"><font style="display:inline;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.16%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">S-</font>6<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:91.78%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#USE_496480"><font style="display:inline;">USE OF PROCEEDS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.16%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">S-</font>7<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:91.78%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#DIL_696924"><font style="display:inline;">DILUTION</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.16%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">S-</font>8<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:91.78%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#DESCRIPTION_19665"><font style="display:inline;">DESCRIPTION OF CAPITAL STOCK</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.16%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">S-</font>9<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:91.78%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#PLAN_389395"><font style="display:inline;">PLAN OF DISTRIBUTION</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.16%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">S-</font>13<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:91.78%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#LEGAL_710258"><font style="display:inline;">LEGAL MATTERS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.16%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">S-</font>14<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:91.78%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#EXP_257999"><font style="display:inline;">EXPERTS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.16%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">S-</font>14<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:91.78%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#WHEREYOU_890137"><font style="display:inline;">WHERE YOU CAN FIND MORE INFORMATION</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.16%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">S-</font>14<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:91.78%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#INCORPORATION_451608"><font style="display:inline;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.16%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">S-</font>14<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:91.78%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#DISCLOSURE_463529"><font style="display:inline;">DISCLOSURE OF COMMISSION&#x2019;S POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITY</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:06.16%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">S-</font>15<font style="display:inline;"></font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Prospectus</font>
		</p>
		<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;text-align:justify;text-justify:inter-ideograph;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:94.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:03.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:94.38%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ABOUTTHISPROSPECTUS_642518"><font style="display:inline;">ABOUT THIS PROSPECTUS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:03.56%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						i<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:94.38%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#SUMMARY_183479"><font style="display:inline;">SUMMARY</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:03.56%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						1<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:94.38%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#RISKFACTORS_173839"><font style="display:inline;">RISK FACTORS</font><font style="display:inline;"></font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:03.56%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						6<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:94.38%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#SPECIALNOTEREGARDINGFORWARD_431950"><font style="display:inline;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:03.56%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						6<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:94.38%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#RATIOOFEARNINGS_880596"><font style="display:inline;">RATIO OF EARNINGS TO COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:03.56%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						7<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:94.38%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#USEOFPROCEEDS_36917"><font style="display:inline;">USE OF PROCEEDS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:03.56%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						8<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:94.38%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#DESCRIPTIONOFCAPITALSTOCK_875907"><font style="display:inline;">DESCRIPTION OF CAPITAL STOCK</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:03.56%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						8<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:94.38%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#DESCRIPTIONOFDEBTSECURITIES_898961"><font style="display:inline;">DESCRIPTION OF DEBT SECURITIES</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:03.56%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						12<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:94.38%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#DESCRIPTIONOFWARRANTS_237117"><font style="display:inline;">DESCRIPTION OF WARRANTS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:03.56%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						19<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:94.38%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#LEGALOWNERSHIPOFSECURITIES_320214"><font style="display:inline;">LEGAL OWNERSHIP OF SECURITIES</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:03.56%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						22<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:94.38%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#PLANOFDISTRIBUTION_606040"><font style="display:inline;">PLAN OF DISTRIBUTION</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:03.56%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						25<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:94.38%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#LEGALMATTERS_475625"><font style="display:inline;">LEGAL MATTERS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:03.56%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						27<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:94.38%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#EXPERT_376494"><font style="display:inline;">EXPERTS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:03.56%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						27<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:94.38%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#WHEREYOUCANFINDMORE_72570"><font style="display:inline;">WHERE YOU CAN FIND MORE INFORMATION</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:03.56%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						27<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:94.38%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#INCORPORATIONOFCERTAIN_434339"><font style="display:inline;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:03.56%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						27<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:94.38%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#DISCLOSUREOFCOMMISSIONPOSITION_515642"><font style="display:inline;">DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITY</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:02.06%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:03.56%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						28<font style="display:inline;"></font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:center;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;background-color: #FFFFFF;text-align:center;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-weight:bold;color:#000000;">ABOU</font><a name="ABOUT_310985"></a><font style="display:inline;font-weight:bold;color:#000000;">T THIS PROSPECTUS</font><font style="display:inline;font-weight:bold;color:#000000;"> SUPPLEMENT</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:center;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">This prospectus</font><font style="display:inline;font-size:10pt;"> supplement</font><font style="display:inline;font-size:10pt;"> is part of a registration statement that we have filed with the Securities and Exchange Commission, or the SEC, utilizing a &#x201C;shelf&#x201D; registration process. Under the shelf registration process, we may offer shares of our common stock having an aggregate offering price of up to $150,000,000. Under this prospectus</font><font style="display:inline;font-size:10pt;"> supplement</font><font style="display:inline;font-size:10pt;">, we may offer shares of our common stock having an aggregate offering price of up to $</font><font style="display:inline;font-size:10pt;">19</font><font style="display:inline;font-size:10pt;">,000,000 from time to time at prices and on terms to be determined by market conditions at the time of offering. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">Before buying any of the common stock that we are offering, we urge you to carefully read this prospectus</font><font style="display:inline;"> supplement and the accompanying prospectus</font><font style="display:inline;color:#000000;">, together with the information incorporated by reference</font><font style="display:inline;"> in this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering when making your investment decision. You should also read and consider the information in the documents we have referred you to under the headings &#x201C;Where You Can Find More Information&#x201D; and &#x201C;Incorporation of Certain Information by Reference.&#x201D;</font><font style="display:inline;color:#000000;"> These documents contain important information that you should consider when making your investment decision. </font>
		</p>
		<p style="margin:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">This prospectus</font><font style="display:inline;color:#000000;"> supplement</font><font style="display:inline;color:#000000;"> describes the terms of this offering of common stock and also adds to and updates information contained in the documents incorporated by reference into this </font><font style="display:inline;">prospectus supplement and the accompanying prospectus</font><font style="display:inline;color:#000000;">. To the extent there is a conflict between the informatio</font><font style="display:inline;color:#000000;">n contained in this prospectus</font><font style="display:inline;color:#000000;"> supplement</font><font style="display:inline;color:#000000;">, on the one hand, and the information contained in any document incorporated by reference into this </font><font style="display:inline;">prospectus supplement and the accompanying prospectus</font><font style="display:inline;color:#000000;">&nbsp;</font><font style="display:inline;color:#000000;">that was filed with the SEC before the date of this prospectus, on the other hand, you should rely on the information in this prospectus</font><font style="display:inline;color:#000000;"> supplement</font><font style="display:inline;color:#000000;">. If any statement in one of these documents is inconsistent with a statement in another document having a later date &#x2014; for example, a document incorporated by reference into this prospectus</font><font style="display:inline;color:#000000;"> supplement</font><font style="display:inline;color:#000000;"> &#x2014; the statement in the document having the later date modifies or supersedes the earlier statement.</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">You should rely only on the information contained in or incorporated by reference in this </font><font style="display:inline;">prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering</font><font style="display:inline;color:#000000;">. We have not, and the sales agent has not, authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not, and the sales agent is not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. </font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">You should assume that the information appearing in this prospectus</font><font style="display:inline;color:#000000;"> supplement</font><font style="display:inline;color:#000000;">, the documents incorporated by reference in this </font><font style="display:inline;">prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering</font><font style="display:inline;color:#000000;">, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus</font><font style="display:inline;color:#000000;"> supplement</font><font style="display:inline;color:#000000;">, the documents incorporated by reference in this</font><font style="display:inline;"> prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering</font><font style="display:inline;color:#000000;">, in their entirety before making an investment decision. </font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">Unless otherwise mentioned or unless the context requires otherwise, all references in this prospectus</font><font style="display:inline;color:#000000;"> supplement</font><font style="display:inline;color:#000000;"> to </font><font style="display:inline;">&#x201C;</font><font style="display:inline;">GlycoMimetics</font><font style="display:inline;">,&#x201D; &#x201C;company,&#x201D; &#x201C;we,&#x201D; &#x201C;us&#x201D; and &#x201C;our&#x201D;</font><font style="display:inline;color:#000000;"> or similar references </font><font style="display:inline;color:#000000;">refer to </font><font style="display:inline;color:#000000;">GlycoMimetics</font><font style="display:inline;color:#000000;">, Inc.</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">This prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein</font><font style="display:inline;color:#000000;"> include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included or incorporated b</font><font style="display:inline;color:#000000;">y reference into this prospectus supplement and the accompanying prospectus</font><font style="display:inline;color:#000000;"> are the property of their respective owners.</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">i</font>

		</p>

		<p style="margin:0pt;line-height:10pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="border-top:2px solid #000000;border-left:2px solid #000000;border-bottom:2px solid #000000;border-right:2px solid #000000;padding-right:2%;padding-left:2%;padding-top:2%;padding-bottom:2%;margin-left:9.29411764705882%;margin-right:9.29411764705882%;"><div style=""><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style=""><p style="margin:0pt;text-align:center;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-weight:bold;color:#000000;">PROSPECTU</font><a name="PROSPECTUS_783439"></a><font style="display:inline;font-weight:bold;color:#000000;">S &nbsp;</font><font style="display:inline;font-weight:bold;color:#000000;">SUPPLEMENT </font><font style="display:inline;font-weight:bold;color:#000000;">SUMMARY</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;color:#000000;">This summary highlights certain information about us, this offering and selected information contained elsewhere in or incorporated by reference into this prospectus</font><font style="display:inline;font-style:italic;color:#000000;"> supplement</font><font style="display:inline;font-style:italic;color:#000000;">. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our common stock. For a more complete understanding of our company and this offering, we encourage you to read and consider carefully</font><font style="display:inline;font-style:italic;color:#000000;"> the more detailed information in</font><font style="display:inline;font-style:italic;"> this prospectus supplement and the accompanying prospectus, including the information incorporated by reference in this prospectus supplement and the accompanying prospectus, and the information included in any free writing prospectus that we have authorized for use in connection with this offering</font><font style="display:inline;font-style:italic;color:#000000;">, including the information under the heading &#x201C;Risk Factors&#x201D; in this prospectu</font><font style="display:inline;font-style:italic;color:#000000;">s supplement</font><font style="display:inline;font-style:italic;color:#000000;"> on page </font><font style="display:inline;font-style:italic;color:#000000;">S-</font><font style="display:inline;font-style:italic;color:#000000;">5</font><font style="display:inline;font-style:italic;color:#000000;"> and </font><font style="display:inline;font-style:italic;color:#000000;">under similar headings </font><font style="display:inline;font-style:italic;color:#000000;">in the documents incorporated by reference into this </font><font style="display:inline;font-style:italic;">prospectus supplement and the accompanying prospectus</font><font style="display:inline;font-style:italic;color:#000000;">.</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We are a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using our expertise in carbohydrate chemistry and knowledge of carbohydrate biology, we are developing a pipeline of proprietary glycomimetics that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. We believe this represents an innovative approach to drug discovery</font><font style="display:inline;font-size:10pt;"> with the potential</font><font style="display:inline;font-size:10pt;"> to treat a wide range of diseases. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Our proprietary glycomimetics platform is based on our expertise in carbohydrate chemistry and our understanding of the role carbohydrates play in key biological processes. Most human proteins are modified by the addition of complex carbohydrates to the surface of the proteins. The addition of these carbohydrate structures affects the functions of these proteins and their interactions with other molecules. Our initial research and development efforts have focused on drug candidates targeting selectins, which are proteins that serve as adhesion molecules and bind to carbohydrates that are involved in the inflammatory component and progression of a wide range of diseases, including hematologic disorders, cancer and cardiovascular disease. For example, we believe that members of the selectin family play a key role in the onset and progression of vaso-occlusive crisis, or VOC, and also in tumor metastasis and resistance to chemotherapy. Inhibiting specific carbohydrates from binding to selectins has long been viewed as a potentially attractive approach for therapeutic intervention. The ability to successfully develop drug-like compounds that inhibit binding with selectins, known as selectin antagonists, has been limited by the complexities of carbohydrate chemistry. We believe our expertise in carbohydrate chemistry and our understanding of carbohydrate-protein binding interactions enable us to design selectin antagonists and other glycomimetics that inhibit the disease-related functions of certain carbohydrates. We believe this expertise and knowledge enable us to develop novel drug candidates to address unmet medical needs. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We are focusing our initial efforts on drug candidates for rare diseases that we believe will qualify for orphan drug designation. We are developing our lead drug candidate, rivipansel, for the treatment of VOC, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. </font><font style="display:inline;font-size:10pt;">Rivipansel is a glycomimetic drug candidate that acts as a pan-selectin antagonist, meaning it binds to all three members of the selectin family, E-,&nbsp;P- and L-selectin. We believe that rivipansel, by acting as a pan-selectin antagonist, inhibits the role that selectins play in VOC. </font><font style="display:inline;font-size:10pt;">Rivipansel has received fast track designation from the U.S. Food and Drug Administration, or FDA, as well as orphan drug designation from the FDA in the United States and from the European Medicines Agency, or EMA, in the European Union, or EU. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We have completed four clinical trials of rivipansel involving a total of 163 subjects. In April 2013, we completed a Phase 2 clinical trial in which 76 patients hospitalized for VOC, ranging from 12 to 60 years old, were treated with the standard of care plus either rivipansel or placebo. In this trial, patients treated with rivipansel experienced reductions in the time to reach resolution of VOC, length of hospital stay and use of opioid analgesics for pain management, in each case as compared to patients receiving placebo. This improvement was seen in both adult and pediatric patients. Adverse event rates and severity were comparable between those treated with rivipansel and those receiving placebo. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We </font><font style="display:inline;">have </font><font style="display:inline;">entered into a license agreement with Pfizer</font><font style="display:inline;"> Inc.</font><font style="display:inline;">, under which Pfizer has rights to </font><font style="display:inline;">further </font><font style="display:inline;">develop and commercialize rivipansel for all indications worldwide. Under the Pfizer agreement, we received an upfront payment of $22.5 million </font><font style="display:inline;">and have received $35.0 million to date upon the achievement of milestones</font><font style="display:inline;">. We are also eligible to receive payments of up to $</font><font style="display:inline;">80</font><font style="display:inline;">.0 million upon the achievement of </font><font style="display:inline;">additional </font><font style="display:inline;">specified development milestones, including the dosing of the first patients in Phase 3 clinical trials for up to two indications and the first commercial sale of a licensed product in the United States and selected European countries for up to two indications</font><font style="display:inline;">;</font><font style="display:inline;"> up to $70.0 million upon </font><font style="display:inline;"></font></p></div><div style="">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">S-</font><font style="display:inline;">1</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="border-top:2px solid #000000;border-left:2px solid #000000;border-bottom:2px solid #000000;border-right:2px solid #000000;padding-right:2%;padding-left:2%;padding-top:2%;padding-bottom:2%;margin-left:9.29411764705882%;margin-right:9.29411764705882%;"><div style=""><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style=""><p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">the achievement of specified regulatory milestones, including the acceptance of our filings for review by regulatory authorities in the United States and Europe for up to two indications</font><font style="display:inline;">;</font><font style="display:inline;"> and up to $135.0 million upon the achievement of specified levels of annual net sales of licensed products. We are also eligible to receive tiered royalties, with percentages ranging from the low double digits to the low teens, based on net sales of rivipansel worldwide, subject to reductions in specified circumstances. </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We are developing our second drug candidate, GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat either acute myeloid leukemia, or AML, or multiple myeloma, or MM, both of which are life-threatening hematologic cancers, and potentially other hematologic cancers as well. </font><font style="display:inline;font-size:10pt;">E-selectin plays a critical role in binding cancer cells within vascular niches in the bone marrow, which prevents the cells from entering circulation where they can be more readily killed by chemotherapy. In separate animal studies, GMI-1271 mobilized AML and MM cancer cells out of the bone marrow, making them more sensitive to chemotherapy. In both the AML and MM studies, tumor burden was significantly reduced in the animals treated with a combination of chemotherapy and GMI-1271 as compared to animals treated with chemotherapy alone. In addition, the combination of GMI-1271 with chemotherapy resulted in improved survival rates for the treated animals, compared to chemotherapy alone. In other animal studies, GMI-1271 appeared to also protect normal cells from some of the side effects of chemotherapy. Animals treated with GMI-1271 and chemotherapy had less severe neutropenia and mucositis and lower bone marrow toxicity as compared to animals treated with chemotherapy alone. We believe that treatment with GMI-1271 results in lower bone marrow toxicity due to its inhibition of E-selectin, which makes stem cells in the bone marrow divide less frequently, thereby protecting them from chemotherapy agents that target rapidly dividing cells</font><font style="display:inline;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have completed </font><font style="display:inline;">a</font><font style="display:inline;">n initial</font><font style="display:inline;">&nbsp;</font><font style="display:inline;">Phase 1 trial</font><font style="display:inline;">&nbsp;</font><font style="display:inline;">in healthy volunteers and have initiated a Phase 1/2 multiple ascending dose-escalation clinical trial in defined populations of patients with AML. We expect to complete the Phase 1 portion of the Phase 1/2 trial</font><font style="display:inline;"> in 2016</font><font style="display:inline;"> and initiate the Phase 2 portion in</font><font style="display:inline;">&nbsp;</font><font style="display:inline;">2016. In December 2015, at the annual meeting of the American Society of Hematology, or ASH, we presented first-in-human clinical data that showed a favorable safety, pharmacokinetic and biomarker profile for GMI-1271. Additionally, we presented preclinical data showing that GMI-1271 could reverse molecular mechanisms of chemotherapy resistance seen in MM.&nbsp;&nbsp;We plan to initiate a clinical trial in patients with MM in the second half of 2016.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have an additional drug candidate, GMI-1359, that simultaneously targets both E-selectin and a chemokine receptor known as CXCR4. GMI-1359 is currently undergoing testing in preclinical models from which we intend to select a target clinical indication, most likely in oncology.&nbsp;&nbsp;&nbsp;We received pre-IND guidance from the FDA in October 2015 and we plan to submit an Investigational New Drug application, or IND, for GMI-1359 for the treatment of hematologic malignancies in the third quarter of 2016.&nbsp;&nbsp;We also plan to initiate a Phase 1 single-dose escalation trial in healthy volunteers in the third quarter of 2016.&nbsp;&nbsp;In December 2015 at the ASH annual meeting, we presented preclinical data showing that GMI-1359 enhanced the ability of chemotherapy to target and improve survival from a form of mutated AML.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">In addition to our programs described above, we are also advancing other preclinical-stage programs. These programs include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9, which we believe may be used for the treatment of fibrosis, cancer and cardiovascular disease</font><font style="display:inline;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We have retained the worldwide development and commercialization rights to all of our drug candidates other than rivipansel. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Our intellectual property portfolio includes ownership of, or exclusive rights to, issued patents and pending patent applications claiming fundamental features of glycomimetic therapeutics, as well as those claiming methods of use for and chemical modifications of our drug candidates. Given the importance of our intellectual property portfolio to our business operations, we intend to vigorously enforce our rights and defend against challenges that have arisen or may arise in this area. Our issued patents directed to rivipansel and methods of use are expected to expire between 2023 and 2030.&nbsp;&nbsp;We have a U.S. patent covering GMI-1271 which is expected to expire in 2032.&nbsp; In addition, we have several pending patent applications covering GMI-1271 and/or methods of using it, the last expiring of which, if issued, currently would be predicted to expire in 2034</font><font style="display:inline;font-size:10pt;">.</font><font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Risks Associated with our Business </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our business is subject to numerous risks and uncertainties, including those highlighted in the section titled &#x201C;Risk Factors&#x201D; immediately following this prospectus </font><font style="display:inline;">supplement </font><font style="display:inline;">summary</font><font style="display:inline;"> and those described </font><font style="display:inline;color:#000000;">under similar headings in the </font><font style="display:inline;color:#000000;"></font></p></div><div style="">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">S-</font><font style="display:inline;">2</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="border-top:2px solid #000000;border-left:2px solid #000000;border-bottom:2px solid #000000;border-right:2px solid #000000;padding-right:2%;padding-left:2%;padding-top:2%;padding-bottom:2%;margin-left:9.29411764705882%;margin-right:9.29411764705882%;"><div style=""><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style=""><p style="margin:6pt 0pt 0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;color:#000000;">documents incorporated by reference into this prospectus</font><font style="display:inline;color:#000000;"> supplement and the accompanying prospectus</font><font style="display:inline;">. These risks include: </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">We have incurred significant losses since our inception. We expect to continue to incur losses over the next several years and may never achieve or maintain profitability</font><font style="display:inline;color:#000000;">. &nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">We </font><font style="display:inline;color:#000000;">will need substantial additional funding to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our drug development programs or potential commercialization efforts.</font><font style="display:inline;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">Our research and development is focused on discovering and developing novel glycomimetic drugs, and we are taking an innovative approach to discovering and developing drugs, which may never lead to marketable drugs</font><font style="display:inline;color:#000000;">. &nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our drug candidates</font><font style="display:inline;color:#000000;">. &nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">If serious adverse or unacceptable side effects are identified during the development of our drug candidates, we may need to abandon or limit the development of some of our drug candidates.</font><font style="display:inline;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">Our success is highly dependent on our existing collaboration with Pfizer, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">If we are unable to obtain and maintain patent protection for our drug candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize drug candidates similar or identical to ours, and our ability to successfully commercialize our drug candidates may be impaired</font><font style="display:inline;color:#000000;">. &nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">If we or our collaborators are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we or they will not be able to commercialize our drug candidates and our ability to generate revenue will be materially impaired.</font><font style="display:inline;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">We face substantial competition, which may result in others discovering, developing or commercializing drugs before or more successfully than we do</font><font style="display:inline;color:#000000;">. &nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Corporate Information </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We were incorporated under the laws of the State of Delaware in April 2003 and commenced operations in May 2003. Our principal executive offices are located at </font><font style="display:inline;font-size:10pt;">9708 Medical Center Drive, Rockville, Maryland</font><font style="display:inline;font-size:10pt;">&nbsp;</font><font style="display:inline;font-size:10pt;">20850</font><font style="display:inline;font-size:10pt;">. Our telephone number is (240)&nbsp;243-1201. Our website is located at http://www.glycomimetics.com. We do not incorporate by reference into this prospectus </font><font style="display:inline;font-size:10pt;">supplement </font><font style="display:inline;font-size:10pt;">the information on, or accessible through, our website, and you should not consider it as part of this prospectus</font><font style="display:inline;font-size:10pt;"> supplement</font><font style="display:inline;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:12pt 0pt 0pt;background-color: #FFFFFF;text-align:center;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;"></font></p></div><div style="">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">S-</font><font style="display:inline;">3</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="border-top:2px solid #000000;border-left:2px solid #000000;border-bottom:2px solid #000000;border-right:2px solid #000000;padding-right:2%;padding-left:2%;padding-top:2%;padding-bottom:2%;margin-left:9.29411764705882%;margin-right:9.29411764705882%;"><div style=""><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style=""><p style="margin:12pt 0pt 0pt;background-color: #FFFFFF;text-align:center;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-weight:bold;color:#000000;">TH</font><a name="THE_804524"></a><font style="display:inline;font-weight:bold;color:#000000;">E OFFERING</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-indent:24.5pt;text-align:center;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;text-align:justify;text-justify:inter-ideograph;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:50.00%;padding:0pt;">
					<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">Common Stock Offered By Us</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:50.00%;padding:0pt;">
					<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">Shares of our common stock having an aggregate offering price of up to $19.0 million.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.00%;padding:0pt;">
					<p style="margin:0pt;background-color: #FFFFFF;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.00%;padding:0pt;">
					<p style="margin:0pt;background-color: #FFFFFF;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.00%;padding:0pt;">
					<p style="margin:0pt;background-color: #FFFFFF;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">Manner of Offering</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.00%;padding:0pt;">
					<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x201C;At-the-market&#x201D; offering that may be made from time to time through our sales agent, Cowen. See &#x201C;Plan of Distribution&#x201D; on page</font><font style="display:inline;font-weight:bold;color:#000000;">&nbsp;</font><font style="display:inline;color:#000000;">S-</font><font style="display:inline;color:#000000;">13</font><font style="display:inline;font-weight:bold;color:#000000;">&nbsp;</font><font style="display:inline;color:#000000;">of this prospectus</font><font style="display:inline;"> supplement</font><font style="display:inline;color:#000000;">.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.00%;padding:0pt;">
					<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.00%;padding:0pt;">
					<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.00%;padding:0pt;">
					<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">Use of Proceeds</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.00%;padding:0pt;">
					<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">We currently intend to use the net proceeds from this offering </font><font style="display:inline;">to conduct planned clinical trials of GMI-1271, to fund the research and development of our preclinical pipeline, including drug discovery, and for working capital and other general corporate purposes</font><font style="display:inline;color:#000000;">. See &#x201C;Use of Proceeds&#x201D; on page</font><font style="display:inline;font-weight:bold;color:#000000;">&nbsp;</font><font style="display:inline;color:#000000;">S-</font><font style="display:inline;">7</font><font style="display:inline;font-weight:bold;">&nbsp;</font><font style="display:inline;color:#000000;">of this prospectus</font><font style="display:inline;"> supplement</font><font style="display:inline;color:#000000;">.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.00%;padding:0pt;">
					<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.00%;padding:0pt;">
					<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.00%;padding:0pt;">
					<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">Risk Factors </font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.00%;padding:0pt;">
					<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">Investing in our common stock involves significant risks. See &#x201C;Risk Factors&#x201D; on page </font><font style="display:inline;color:#000000;">S-</font><font style="display:inline;">5</font><font style="display:inline;font-weight:bold;">&nbsp;</font><font style="display:inline;color:#000000;">of this prospectus</font><font style="display:inline;"> supplement</font><font style="display:inline;color:#000000;">, and under similar headings in other documents incorporated by reference into this prospectus</font><font style="display:inline;"> supplement and the accompanying prospectus</font><font style="display:inline;color:#000000;">.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:50.00%;padding:0pt;">
					<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">NASDAQ Global Market Symbol</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:50.00%;padding:0pt;">
					<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x201C;GLYC&#x201D;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;border-bottom:1pt none #D9D9D9 ;text-align:center;font-weight:bold;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#0000FF;text-align:center;font-weight:bold;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:center;font-weight:bold;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">S-</font><font style="display:inline;">4</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:center;font-weight:bold;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">RISK</font><a name="RISK_367046"></a><font style="display:inline;"> FACTORS</font>
		</p>
		<p style="margin:0pt;text-align:left;text-indent:18pt;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described </font><font style="display:inline;font-style:italic;">below</font><font style="display:inline;font-style:italic;"> and under </font><font style="display:inline;font-style:italic;">the section titled &#x201C;Risk Factors&#x201D;</font><font style="display:inline;font-style:italic;"> in our Annual Report on Form 10-K for the year ended December 31, </font><font style="display:inline;font-style:italic;">2015</font><font style="display:inline;font-style:italic;">, as updated by our annual, quarterly and other reports and documents that are incorporated by reference into this </font><font style="display:inline;font-style:italic;">prospectus supplement and the accompanying </font><font style="text-decoration:none;text-decoration:none;display:inline;font-style:italic;">prospectus</font><font style="display:inline;font-style:italic;"> and any </font><font style="text-decoration:none;text-decoration:none;display:inline;font-style:italic;">free writing prospectus</font><font style="display:inline;font-style:italic;"> with respect to this offering filed by us with the SEC</font><font style="display:inline;font-style:italic;">, before deciding whether to </font><font style="display:inline;font-style:italic;">invest in our common stock</font><font style="display:inline;font-style:italic;">. Each of the risk factors could adversely affect our business, operating results and financial condition, as well as adversely affect the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment. </font><font style="display:inline;font-style:italic;">Additional risks not presently known to us or that we currently believe are immaterial may also significantly </font><font style="display:inline;font-style:italic;">impair our business operations. Please also read carefully the section below titled &#x201C;Special Note Regarding Forward-Looking Statements.&#x201D;</font>
		</p>
		<p style="margin:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">Additional </font><font style="display:inline;font-weight:bold;color:#000000;">Risks Related to This Offering</font>
		</p>
		<p style="margin:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">You </font><font style="display:inline;font-weight:bold;color:#000000;">may</font><font style="display:inline;font-weight:bold;color:#000000;"> experience dilution.</font>
		</p>
		<p style="margin:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">The offering price per share in this offering may exceed the net tangible book value per share of our common stock outstanding prior to this offering. Assuming that an aggregate of </font><font style="display:inline;">4,185,022</font><font style="display:inline;color:#000000;"> shares of our common stock are sold at a price of $</font><font style="display:inline;">4.54</font><font style="display:inline;color:#000000;"> per share, the last reported sale price of our common stock on the Exchange on </font><font style="display:inline;">February 29</font><font style="display:inline;">, 201</font><font style="display:inline;">6</font><font style="display:inline;color:#000000;">, for aggregate gross proceeds of $</font><font style="display:inline;color:#000000;">19</font><font style="display:inline;color:#000000;">.0</font><font style="display:inline;color:#000000;">&nbsp;million, and after deducting commissions and estimated offering expenses payable by us, you w</font><font style="display:inline;color:#000000;">ould</font><font style="display:inline;color:#000000;"> experience immediate dilution of $</font><font style="display:inline;">2.01 </font><font style="display:inline;color:#000000;">per share, representing the difference between our as adjusted net tangible book value per share as of </font><font style="display:inline;color:#000000;">December 31</font><font style="display:inline;color:#000000;">, 2015</font><font style="display:inline;color:#000000;">,</font><font style="display:inline;color:#000000;"> after giving effect to this offering</font><font style="display:inline;color:#000000;">,</font><font style="display:inline;color:#000000;"> and the assumed offering price. The exercise of outstanding stock options and warrants w</font><font style="display:inline;color:#000000;">ould</font><font style="display:inline;color:#000000;"> result in further dilution of your investment. See the section entitled &#x201C;Dilution&#x201D; below for a more detailed illustration of the dilution you would incur if you participate in this offering. </font><font style="display:inline;color:#000000;">Because the sales of the shares offered hereby will be made directly into the market or in negotiated transactions, the prices at which we sell these shares will vary and these variations may be significant. Purchasers of the shares we sell, as well as our existing shareholders, will experience significant dilution if we sell shares at prices significantly below the price at which they invested.</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;border-top:1pt none #D9D9D9 ;color:#000000;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">You may experience future dilution as a result of future equity offerings.</font>
		</p>
		<p style="margin:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">T</font><font style="display:inline;color:#000000;">o raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering at a price per share that is less than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by investors in this offering.&nbsp;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">Our management might apply the net proceeds from this offering in ways with which you do not agree and in ways that may impair the value of your investment.</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;border-top:1pt none #D9D9D9 ;color:#000000;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">We currently intend to use the net proceeds from this offering </font><font style="display:inline;font-size:10pt;">to conduct planned clinical trials of GMI-1271, to fund the research and development of our preclinical pipeline, including drug discovery, and for working capital and other general corporate purposes</font><font style="display:inline;color:#000000;font-size:10pt;">. Pending these uses, we expect to invest the net proceeds in short-term, interest-bearing securities</font><font style="display:inline;color:#000000;font-size:10pt;">. Our management has broad discretion as to the use of these proceeds and you will be relying on the judgment of our management regarding the application of these proceeds. We might apply these proceeds in ways with which you do not agree, or in ways that do not yield a favorable return. If our management applies these proceeds in a manner that does not yield a significant return, if any, on our investment of these net proceeds, it could compromise our ability to pursue our growth strategy and adversely affect the market price of our common stock.</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">S-</font><font style="display:inline;">5</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-weight:bold;">SPECIAL NOTE</font><a name="SPECIALNOTE_124015"></a><font style="display:inline;font-weight:bold;"> REGARDING FORWARD-LOOKING STATEMENTS</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">This prospectus supplement and the accompanying prospectus, the documents we file with the SEC that are incorporated by reference in this prospectus supplement and the accompanying prospectus and any free writing prospectus that we have authorized for use in connection with this offering, contain &#x201C;forward-looking statements&#x201D; within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act. </font><font style="display:inline;font-size:10pt;">These are based on our management&#x2019;s current beliefs, expectations and assumptions about future events, conditions and results and on information currently available to us. Discussions containing these forward-looking statements may be found, among other places, in the Sections entitled &#x201C;Business,&#x201D; &#x201C;Risk Factors&#x201D; and &#x201C;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201D; incorporated by reference from our most recent Annual Report on </font><font style="text-decoration:none;text-decoration:none;display:inline;font-size:10pt;">Form 10-K</font><font style="display:inline;font-size:10pt;"> and in our Quarterly Reports on Form 10-Q, as well as any amendments thereto, filed with the SEC. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Any statements in this prospectus</font><font style="display:inline;font-size:10pt;"> supplement and the accompanying prospectus</font><font style="display:inline;font-size:10pt;">, or incorporated herein</font><font style="display:inline;font-size:10pt;"> or therein</font><font style="display:inline;font-size:10pt;">, about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. </font><font style="display:inline;font-size:10pt;">T</font><font style="display:inline;font-size:10pt;">hese forward-looking statements include statements regarding: </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:25pt;"><p style="width:25pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;text-align:left;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">our plans to develop and commercialize our glycomimetic drug candidates; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -10.8pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:25pt;"><p style="width:25pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;text-align:left;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">our planned clinical trials for our drug candidates GMI-1271 and GMI-1359; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -10.8pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:25pt;"><p style="width:25pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;text-align:left;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">our ability to achieve anticipated milestones under our collaboration with Pfizer for our drug candidate rivipansel; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -10.8pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:25pt;"><p style="width:25pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;text-align:left;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the timing of and our ability to obtain and maintain regulatory approvals for our drug candidates; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -10.8pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:25pt;"><p style="width:25pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;text-align:left;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the clinical utility of our drug candidates; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -10.8pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:25pt;"><p style="width:25pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;text-align:left;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">our commercialization, marketing and manufacturing capabilities and strategy; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -10.8pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:25pt;"><p style="width:25pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;text-align:left;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">our intellectual property position; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -10.8pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:25pt;"><p style="width:25pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;text-align:left;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">our ability to identify additional drug candidates with significant commercial potential that are consistent with our commercial objectives; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -10.8pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:25pt;"><p style="width:25pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;text-align:left;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">our estimates regarding future revenues, expenses and needs for additional financing; and </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -10.8pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:25pt;"><p style="width:25pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;text-align:left;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">our beliefs about our capital expenditure requirements and </font><font style="display:inline;color:#000000;">the length of time over which</font><font style="display:inline;color:#000000;"> our capital resources will be sufficient to meet our anticipated cash requirements. </font></p></td></tr></table></div>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;color:#000000;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">In some cases, you can identify forward-looking statements by terms such as &#x201C;may,&#x201D; &#x201C;will,&#x201D; &#x201C;should,&#x201D; &#x201C;could,&#x201D; &#x201C;would,&#x201D; &#x201C;expect,&#x201D; &#x201C;plan,&#x201D; &#x201C;anticipate,&#x201D; &#x201C;believe,&#x201D; &#x201C;estimate,&#x201D; &#x201C;project,&#x201D; &#x201C;predict,&#x201D; &#x201C;potential&#x201D; and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss in greater detail many of these risks under the heading &#x201C;Risk Factors&#x201D; contained in this prospectus</font><font style="display:inline;font-size:10pt;"> supplement and the accompanying prospectus</font><font style="display:inline;font-size:10pt;">, in any free writing prospectuses we may authorize for use in connection with a specific offering, and in our most recent annual report on </font><font style="text-decoration:none;text-decoration:none;display:inline;font-size:10pt;">Form 10-K</font><font style="display:inline;font-size:10pt;">, as well as any amendments thereto reflected in subsequent filings with the SEC, which are incorporated by reference into this prospectus</font><font style="display:inline;font-size:10pt;"> supplement and the accompanying prospectus</font><font style="display:inline;font-size:10pt;"> in their entirety. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should read this prospectus</font><font style="display:inline;font-size:10pt;"> supplement and the accompanying prospectus</font><font style="display:inline;font-size:10pt;">, together with the documents we have filed with the SEC that are incorporated by reference and any free writing prospectus that we may authorize for use in connection with this offering completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements</font><font style="display:inline;font-size:10pt;">. &nbsp;</font><font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;"></font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">S-</font><font style="display:inline;">6</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;text-align:center;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-weight:bold;color:#000000;">USE</font><a name="USE_496480"></a><font style="display:inline;font-weight:bold;color:#000000;"> OF PROCEEDS</font>
		</p>
		<p style="margin:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">We </font><font style="display:inline;color:#000000;">may issue and sell shares of our common stock having aggr</font><font style="display:inline;color:#000000;">egate </font><font style="display:inline;color:#000000;">sales proceeds of up to $</font><font style="display:inline;color:#000000;">19</font><font style="display:inline;color:#000000;">.0</font><font style="display:inline;color:#000000;">&nbsp;million from time to time.</font><font style="display:inline;color:#000000;">&nbsp;</font><font style="display:inline;color:#000000;">Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time.</font><font style="display:inline;"> There can be no assurance that we will sell any shares under or fully utilize the sales agreement with Cowen as a source of financing</font><font style="display:inline;color:#000000;">.</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We currently intend to use the net proceeds f</font><font style="display:inline;">rom this offering primarily </font><font style="display:inline;">to conduct planned clinical trials of GMI-1271, to fund the research and development of our preclinical pipeline, including drug discovery, and for working capital and other general corporate purposes</font><font style="display:inline;">. &nbsp;</font><font style="display:inline;">We may also use a portion of the net proceeds to invest in or acquire businesses or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus</font><font style="display:inline;"> supplement</font><font style="display:inline;">. &nbsp;</font><font style="display:inline;">Pending these uses, we expect to invest the net proceeds in short-term, interest-bearing securities</font><font style="display:inline;">.</font>
		</p>
		<p style="margin:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;"></font>
		</p>
		<p style="margin:0pt;line-height:11pt;text-align:center;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">S-</font><font style="display:inline;">7</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:11pt;text-align:center;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-weight:bold;color:#000000;">DI</font><a name="DIL_696924"></a><font style="display:inline;font-weight:bold;color:#000000;">LUTION</font>
		</p>
		<p style="margin:0pt;line-height:9pt;text-align:center;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;line-height:11.5pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">Our net tangible book value as of </font><font style="display:inline;color:#000000;">December 31</font><font style="display:inline;color:#000000;">, 2015</font><font style="display:inline;color:#000000;"> was approximately $</font><font style="display:inline;color:#000000;">40.5</font><font style="display:inline;">&nbsp;</font><font style="display:inline;color:#000000;">million, or $</font><font style="display:inline;color:#000000;">2.</font><font style="display:inline;color:#000000;">12</font><font style="display:inline;color:#000000;"> per share. Net tangible book value per share is determined by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of </font><font style="display:inline;color:#000000;">December 31</font><font style="display:inline;color:#000000;">, 201</font><font style="display:inline;color:#000000;">5</font><font style="display:inline;color:#000000;">. Dilution with respect to net tangible book value per share represents the difference between the amount per share paid by purchasers of shares of common stock in this offering and the net tangible book value per share of our common stock immediately after this offering.</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;line-height:9pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;line-height:11.5pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">After giving effect to the sale of </font><font style="display:inline;">4,185,022</font><font style="display:inline;">&nbsp;</font><font style="display:inline;color:#000000;">shares of our common stock in this offering at an assumed offering price of $</font><font style="display:inline;">4.54 </font><font style="display:inline;color:#000000;">per share, </font><font style="display:inline;color:#000000;">the last reported sale price of our common stock on the Exchange on </font><font style="display:inline;color:#000000;">February 29</font><font style="display:inline;color:#000000;">, 201</font><font style="display:inline;color:#000000;">6</font><font style="display:inline;color:#000000;">, &nbsp;</font><font style="display:inline;color:#000000;">and after deducting estimated offering commissions and offering expenses payable by us, our as adjusted net tangible book value as of </font><font style="display:inline;color:#000000;">December 31</font><font style="display:inline;color:#000000;">, 2015</font><font style="display:inline;color:#000000;">&nbsp;</font><font style="display:inline;color:#000000;">would have been approximately $</font><font style="display:inline;">58.8</font><font style="display:inline;color:#000000;"> million, or $</font><font style="display:inline;">2.53</font><font style="display:inline;color:#000000;"> per share. This represents an immediate increase in net tangible book value of $</font><font style="display:inline;">0.41 </font><font style="display:inline;color:#000000;">per share to existing stockholders and immediate dilution of $</font><font style="display:inline;">2.01</font><font style="display:inline;color:#000000;"> per share to investors purchasing our common stock in this offering at the public offering price. The following table illustrates this dilution on a per share basis:</font>
		</p>
		<p style="margin:0pt;line-height:9pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;background-color: #FFFFFF;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:85.58%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:11pt;text-indent: -12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Assumed public offering price per share</font></p>
				</td>
				<td valign="top" style="width:02.06%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.06%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:03.60%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.54&nbsp;
				</td>
				<td valign="top" style="width:00.52%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:85.58%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:11pt;text-indent: -12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net tangible book value per share of as </font><font style="display:inline;color:#000000;">December 31, 2015</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:04.12%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.12&nbsp;
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.60%;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.52%;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:85.58%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:11pt;text-indent: -12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Increase in net tangible book value per share attributable to this offering</font></p>
				</td>
				<td valign="top" style="width:02.06%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:04.12%;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.41&nbsp;
				</td>
				<td valign="top" style="width:02.06%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.60%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.52%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:85.58%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:11pt;text-indent: -12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">As adjusted net tangible book value per share as of </font><font style="display:inline;color:#000000;">December 31, 2015</font><font style="display:inline;">, after giving effect to this offering</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.12%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:03.60%;border-bottom:1pt solid #000000 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.53&nbsp;
				</td>
				<td valign="top" style="width:00.52%;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:85.58%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:11pt;text-indent: -12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Dilution per share to investors purchasing our common stock in this offering</font></p>
				</td>
				<td valign="top" style="width:02.06%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.12%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:02.06%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:03.60%;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.01&nbsp;
				</td>
				<td valign="top" style="width:00.52%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:9pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;line-height:11.5pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">The above discussion and table are based on </font><font style="display:inline;">19,</font><font style="display:inline;">050</font><font style="display:inline;">,</font><font style="display:inline;">204</font><font style="display:inline;">&nbsp;</font><font style="display:inline;color:#000000;">shares outstanding as of </font><font style="display:inline;color:#000000;">December 31</font><font style="display:inline;color:#000000;">, 2015</font><font style="display:inline;color:#000000;">, and exclude:</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;line-height:9pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">578,687 </font><font style="display:inline;color:#000000;">shares of common stock issuable upon the exercise of warrants outstanding as of</font><font style="display:inline;color:#000000;"> December 31, 2015</font><font style="display:inline;color:#000000;">, having a weighted average exercise price of $0.40 per share;</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">2,228,525</font><font style="display:inline;color:#000000;"> shares of common stock issuable upon the exercise of stock options outstanding as of </font><font style="display:inline;color:#000000;">December 31, 2015</font><font style="display:inline;color:#000000;">, having a weighted average exercise price of $5.88</font><font style="display:inline;color:#000000;">&nbsp;</font><font style="display:inline;color:#000000;"> per share; </font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="color:#000000;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;color:#000000;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="color:#000000;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">4,833 </font><font style="display:inline;color:#000000;">shares of common stock issuable upon the vesting of restricted stock units outstanding as of </font><font style="display:inline;color:#000000;">December 31, 2015; and</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">an aggregate of </font><font style="display:inline;color:#000000;">455,005</font><font style="display:inline;color:#000000;">&nbsp;</font><font style="display:inline;color:#000000;">shares of common stock reserved for future issuance under our equity incentive and employee stock purchase plans as of </font><font style="display:inline;color:#000000;">December 31, 2015</font><font style="display:inline;color:#000000;">. &nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt;background-color: #FFFFFF;line-height:9pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;line-height:11.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The table above assumes for illustrative purposes that an aggregate of </font><font style="display:inline;">4,185,022</font><font style="display:inline;">&nbsp;</font><font style="display:inline;">shares of our common stock are sold during the term of the sales agreement with Cowen at a price of $</font><font style="display:inline;">4.54</font><font style="display:inline;">&nbsp;</font><font style="display:inline;">per share, the last reported sal</font><font style="display:inline;">e price of our common stock on t</font><font style="display:inline;">he </font><font style="display:inline;">Exchange</font><font style="display:inline;">&nbsp;</font><font style="display:inline;">on </font><font style="display:inline;">February 29</font><font style="display:inline;">, 201</font><font style="display:inline;">6</font><font style="display:inline;">, fo</font><font style="display:inline;">r aggregate gross proceeds of $</font><font style="display:inline;">19</font><font style="display:inline;">.0 million</font><font style="display:inline;">. The shares subject to the sales agreement with Cowen are being sold from time to time at various prices. An increase of $</font><font style="display:inline;">1.00</font><font style="display:inline;"> per share in the price at which the shares are sold from the assumed offering price of $</font><font style="display:inline;">4.54 </font><font style="display:inline;">per share shown in the table above, assuming all of our common sto</font><font style="display:inline;">ck in the aggregate amount of $</font><font style="display:inline;">19</font><font style="display:inline;">.0 million</font><font style="display:inline;"> during the term of the sales agreement with Cowen is sold at that price, would increase our adjusted net tangible book value per share after the offering to $</font><font style="display:inline;">2.61</font><font style="display:inline;"> per share and would increase the dilution in net tangible book value per share to new investors in this offering to $</font><font style="display:inline;">2.93</font><font style="display:inline;"> per share, after deducting commissions and estimated aggregate offering expenses payable by us. A decrease of $</font><font style="display:inline;">1.00</font><font style="display:inline;"> per share in the price at which the shares are sold from the assumed offering price of $</font><font style="display:inline;">4.54</font><font style="display:inline;"> per share shown in the table above, assuming all of our common stoc</font><font style="display:inline;">k in the aggregate amount of $</font><font style="display:inline;">19</font><font style="display:inline;">.0 million</font><font style="display:inline;"> during the term of the sales agreement with Cowen is sold at that price, would decrease our adjusted net tangible book value per share after the offering to $</font><font style="display:inline;">2.41</font><font style="display:inline;">&nbsp;</font><font style="display:inline;">per share and would decrease the dilution in net tangible book value per share to new investors in this offering to $</font><font style="display:inline;">1.13</font><font style="display:inline;">&nbsp;</font><font style="display:inline;">per share, after deducting commissions and estimated aggregate offering expenses payable by us. This information is supplied for illustrative purposes only. </font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;line-height:9pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;line-height:11.5pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">To the extent that outstanding options or warrants outstanding as of </font><font style="display:inline;color:#000000;">December 31</font><font style="display:inline;color:#000000;">, 2015</font><font style="display:inline;color:#000000;"> have been or may be exercised or other shares issued, investors purchasing our common stock in this offering may experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.</font>
		</p>
		<p style="margin:0pt;text-align:center;border-bottom:1pt none #D9D9D9 ;text-indent:18pt;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">S-</font><font style="display:inline;">8</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;text-align:center;border-bottom:1pt none #D9D9D9 ;text-indent:18pt;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-weight:bold;">DESCRIPTIO</font><a name="DESCRIPTION_19665"></a><font style="display:inline;font-weight:bold;">N OF CAPITAL STOCK</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;text-indent:18pt;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of the date of this prospectus</font><font style="display:inline;"> supplement</font><font style="display:inline;">, our certificate of incorporation authorizes us to issue 100,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share. As of December 31, 2015, 19,050,204 shares of common stock were outstanding and no shares of preferred stock were outstanding</font><font style="display:inline;color:#000000;">.</font>
		</p>
		<p style="margin:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:left;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following summary description of our capital stock is based on the provisions of our certificate of incorporation, as well as our bylaws and the applicable provisions of the Delaware General Corporation Law. This information is qualified entirely by reference to the applicable provisions of our certificate of incorporation, bylaws and the Delaware General Corporation Law</font><font style="display:inline;color:#000000;">, which are incorporated by reference as exhibits into the </font><font style="display:inline;color:#000000;">registration statement of which this prospectus supplement and the accompanying prospectus are a part</font><font style="display:inline;color:#000000;">.</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:left;border-top:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;font-weight:bold;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Common Stock</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders. The holders of our common stock do not have cumulative voting rights in the election of directors. Subject to preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably such dividends as may be declared by our board of directors out of legally available funds. Upon our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any outstanding shares of preferred stock. Holders of common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to our common stock. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Additional shares of authorized common stock may be issued, as authorized by our board of directors from time to time, without stockholder approval, except as may be required by applicable stock exchange requirements.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The rights of the holders of our common stock are subject to, and may be adversely affected by, the rights of holders of shares of any preferred stock that we may designate and issue in the future</font><font style="display:inline;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Registration Rights </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We and the some of the holders of our common stock have entered into </font><font style="display:inline;font-size:10pt;">a second amended and restated investor rights agreement, dated as of October 20, 2009, or the</font><font style="display:inline;font-size:10pt;"> investor rights agreement. The registration rights provisions of this agreement provide those holders with demand, piggyback and Form S-3 registration rights with respect to the shares of our common stock currently held by them. </font><font style="display:inline;font-size:10pt;">The following information is qualified entirely by reference to the applicable provisions of the investor rights agreement</font><font style="display:inline;color:#000000;font-size:10pt;">, which is incorporated by reference as </font><font style="display:inline;color:#000000;font-size:10pt;">an exhibit</font><font style="display:inline;color:#000000;font-size:10pt;"> into the registration statement of which this prospectus supplement and the accompanying prospectus are a part.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;font-size:10pt;">Demand Registration Rights </font>
		</p>
		<p style="margin:0pt 0pt 0pt 24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The holders of at least 40% of the shares held by the parties to the investor rights agreement have the right to demand that we file up to a total of two registration statements, as long as the anticipated aggregate offering price, net of underwriting discounts and commissions, would exceed $10.0 million. These registration rights are subject to specified conditions and limitations, including the right of the underwriters, if any, to limit the number of shares included in any such registration under specified circumstances. Upon such a request, we are required to effect the registration as soon as reasonably possible. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;font-size:10pt;">Piggyback Registration Rights </font>
		</p>
		<p style="margin:0pt 0pt 0pt 24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">If we propose to register any of our securities under the Securities Act either for our own account or for the account of other stockholders, the parties to the investor rights agreement with piggyback registration rights will each be entitled to notice of the registration and will be entitled to include their shares of common stock in the registration statement. These piggyback registration rights are subject to specified conditions and limitations, including the right of the underwriters to limit the number of shares included in any such registration under specified circumstances. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">S-</font><font style="display:inline;">9</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">Pursuant to the terms of our currently outstanding warrant to purchase common stock held by a prior lender, the holder has similar piggyback registration rights with respect to the shares of our common stock issuable upon exercise of the warrant. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;font-size:10pt;">Registration on Form S-3 </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">If we are eligible to file a registration statement on Form S-3, the parties to the investor rights agreement are entitled, upon their written request, to have such shares registered by us on a Form S-3 registration statement at our expense, provided that such requested registration has an anticipated aggregate offering size to the public of at least $1.0 million and subject to other specified conditions and limitations. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;font-size:10pt;">Expenses of Registration </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We will pay all expenses relating to any demand, piggyback or Form S-3 registration, other than underwriting discounts and commissions, subject to specified conditions and limitations. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;font-size:10pt;">Termination of Registration Rights </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The registration rights granted under the investor rights agreement will terminate upon the seventh anniversary of the completion of our initial public offering, which would be in January 2021, or, if earlier, with respect to a particular holder, at such time as that holder and its affiliates may sell all of their shares of common stock pursuant to Rule 144 under the Securities Act of 1933, as amended, without any restrictions on volume. </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;font-weight:bold;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Preferred</font><font style="display:inline;"> Stock</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Pursuant to our amended and restated certificate of incorporation, </font><font style="display:inline;font-size:10pt;">our board of directors </font><font style="display:inline;font-size:10pt;">has</font><font style="display:inline;font-size:10pt;"> the authority, without further action by our stockholders, to issue up to 5,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of us and may adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. It is not possible to state the actual effect of the issuance of any shares of preferred stock on the rights of holders of common stock until the board of directors determines the specific rights attached to that preferred stock</font><font style="display:inline;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;border-top:1pt none #D9D9D9 ;color:#000000;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">Warrants</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have outstanding immediately exercisable warrants to purchase: </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">an aggregate of 1,544 shares of our common stock at an exercise price of $25.92 per share, which warrants expire in October 2016</font><font style="display:inline;color:#000000;">;</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">an aggregate of </font><font style="display:inline;color:#000000;">259,907</font><font style="display:inline;color:#000000;"> shares of our common stock at an exercise price of $0.33 per share, which warrants expire in July 2018; and</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">an aggregate of 317,236 shares of our common stock at an exercise price of $0.33 per share, which warrants expire in January 2019.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Each of our outstanding warrants has a net exercise provision under which the holder may, in lieu of payment of the exercise price in cash, surrender the warrant and receive a net amount of shares based on the fair market value of our common stock at the time of exercise of the warrant after deduction of the aggregate exercise price. The warrants also </font><font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">S-</font><font style="display:inline;">10</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">contain provisions for the adjustment of the exercise price and the number of shares issuable upon the exercise of the warrant in the event of certain stock dividends, stock splits, reorganizations, reclassifications and consolidations. </font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">Anti-Takeover Provisions</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;font-size:10pt;">Charter Documents.</font><font style="display:inline;font-size:10pt;"> Our amended and restated certificate of incorporation and amended and related bylaws,&nbsp;&nbsp;each as amended to date, include a number of provisions that may have the effect of deterring hostile takeovers or delaying or preventing changes in control or management of our company. First, our board of directors is classified into three classes of directors. Under Delaware law, directors of a corporation with a classified board may be removed only for cause unless the corporation&#x2019;s certificate of incorporation provides otherwise. Our certificate of incorporation does not provide otherwise. In addition, our certificate of incorporation provides that all stockholder action must be effected at a duly called meeting of stockholders and not by a consent in writing. Further, our bylaws limit who may call special meetings of the stockholders. Our certificate of incorporation does not include a provision for cumulative voting for directors. Under cumulative voting, a minority stockholder holding a sufficient percentage of a class of shares may be able to ensure the election of one or more directors. Finally, our bylaws establish procedures, including advance notice procedures, with regard to the nomination of candidates for election as directors and stockholder proposals. These and other provisions of our certificate of incorporation and bylaws and Delaware law could discourage potential acquisition proposals and could delay or prevent a change in control or management of our company. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;font-size:10pt;">Delaware Takeover Statute. </font><font style="display:inline;font-size:10pt;">We are subject to Section&nbsp;203 of the General Corporation Law of the State of Delaware, or DGCL, which regulates acquisitions of some Delaware corporations. Section&nbsp;203 generally prohibits a publicly held Delaware corporation from engaging in a &#x201C;business combination&#x201D; with an &#x201C;interested stockholder&#x201D; for a period of three years following the date of the transaction in which the person became an interested stockholder, unless: </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the board of directors of the corporation approved the business combination or the other transaction in which the person became an interested stockholder prior to the date of the business combination or other transaction; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">upon consummation of the transaction that resulted in the person becoming an interested stockholder, the person owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding shares owned by persons who are directors and also officers of the corporation and shares issued under employee stock plans under which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">on or subsequent to the date the person became an interested stockholder, the board of directors of the corporation approved the business combination and the stockholders of the corporation authorized the business combination at an annual or special meeting of stockholders by the affirmative vote of at least 66-2/3% of the outstanding stock of the corporation not owned by the interested stockholder. </font></p></td></tr></table></div>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Section&nbsp;203 of the DGCL defines a &#x201C;business combination&#x201D; to include any of the following: </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">any merger or consolidation involving the corporation and the interested stockholder; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">any sale, transfer, pledge or other disposition of 10% or more of the corporation&#x2019;s assets or outstanding stock involving the interested stockholder; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any of its stock to the interested stockholder; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">any transaction involving the corporation that has the effect of increasing the proportionate share of its stock owned by the interested stockholder; or </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;text-indent: -18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. </font></p></td></tr></table></div>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">S-</font><font style="display:inline;">11</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">In general, Section&nbsp;203 defines an &#x201C;interested stockholder&#x201D; as any person who, together with the person&#x2019;s affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#x2019;s voting stock. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Section&nbsp;203 could depress our stock price and delay, discourage or prohibit transactions not approved in advance by our board of directors, such as takeover attempts that might otherwise involve the payment to our stockholders of a premium over the market price of our common stock. </font>
		</p>
		<p style="margin:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;font-weight:bold;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Transfer Agent and Registrar</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:left;border-bottom:1pt none #D9D9D9 ;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;background-color: #FFFFFF;">The </font><font style="display:inline;">transfer agent and registrar for our common stock is American Stock Transfer&nbsp;&amp; Trust Company, and its address is 6201 15th Street, Brooklyn, NY 11219.</font><font style="display:inline;"> &nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;border-bottom:1pt none #D9D9D9 ;font-weight:bold;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;border-top:1pt none #D9D9D9 ;font-weight:bold;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Listing on the </font><font style="display:inline;">NASDAQ</font><font style="display:inline;"> Global Market</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:left;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:left;border-top:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our common stock is listed on the </font><font style="display:inline;">NASDAQ</font><font style="display:inline;"> Global Market under the symbol &#x201C;</font><font style="display:inline;">GLYC</font><font style="display:inline;">&#x201D;.</font>
		</p>
		<p style="margin:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;text-transform:uppercase;color:#000000;"></font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;text-transform:uppercase;color:#000000;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">S-</font><font style="display:inline;">12</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;text-align:center;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-weight:bold;text-transform:uppercase;color:#000000;">Pla</font><a name="PLAN_389395"></a><font style="display:inline;font-weight:bold;text-transform:uppercase;color:#000000;">n Of Distribution</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have entered into a sales agreement with Cowen, under which we may issue and sell from time to time up to $</font><font style="display:inline;">40.0 million</font><font style="display:inline;"> of our common stock through Cowen as our sales agent.&nbsp; </font><font style="display:inline;color:#000000;">This prospectus supplement is only offering $19.0 million in shares of our common stock. We will be required to file another prospectus supplement in the event we want to offer more than $19.0 million in shares of our common stock in accordance with the sales agreement.&nbsp; </font><font style="display:inline;">Sales of our common stock, if any, will be made at market prices by any method that is deemed to be an &#x201C;at the market&#x201D; offering as defined in Rule 415 under the Securities Act, including sales made directly on </font><font style="display:inline;">the </font><font style="display:inline;">Exchange or any other trading market for our common stock, or sales to or through a market maker other than on an exchange.&nbsp;&nbsp;If authorized by us in writing, Cowen may also sell our shares of common stock by any other method permitted by law, including negotiated transactions, and Cowen may also purchase shares of our common stock as principal.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Cowen will offer our common stock subject to the terms and conditions of the sales agreement on a daily basis or as otherwise agreed upon by us and Cowen. We will designate the maximum amount of common stock to be sold through Cowen on a daily basis or otherwise determine such maximum amount together with Cowen.&nbsp;&nbsp;Subject to the terms and conditions of the sales agreement, Cowen will use its commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by us.&nbsp;&nbsp;We may instruct Cowen not to sell common stock if the sales cannot be effected at or above the price designated by us in any such instruction.&nbsp;&nbsp;Cowen or we may suspend the offering of our common stock being made through Cowen under the sales agreement upon proper notice to the other party.&nbsp;&nbsp;Cowen and we each have the right, by giving written notice as specified in the sales agreement, to terminate the sales agreement in each party&#x2019;s sole discretion at any time.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The aggregate compensation payable to Cowen as sales agent equals 3.0% of the gross sales price of the shares sold through it pursuant to the sales agreement. </font><font style="display:inline;color:#000000;">In addition, we have agreed to reimburse Cowen for fees and disbursements related to its legal counsel in an amount not to exceed </font><font style="display:inline;color:#000000;">$50,000, and for certain other expenses, including Cowen&#x2019;s FINRA counsel fees in an amount up to $12,500.</font><font style="display:inline;color:#000000;"> &nbsp; &nbsp;</font><font style="display:inline;">We estimate that the total expenses of the offering payable by us, excluding commissions payable to Cowen under the sales agreement, will be approximately $</font><font style="display:inline;">150,000</font><font style="display:inline;">.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The remaining sales proceeds, after deducting any expenses payable by us and any transaction fees imposed by any governmental, regulatory, or self-regulatory organization in connection with the sales, will equal our net proceeds for the sale of such common stock.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Cowen will provide written confirmation to us following the close of trading on the Exchange on each day in which common stock is sold through it as sales agent under the sales agreement.&nbsp;&nbsp;Each confirmation will include the number of shares of common stock sold through it as sales agent on that day, the volume weighted average price of the shares sold, the percentage of the daily trading volume and the net proceeds to us.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We will report at least quarterly the number of shares of common stock sold through Cowen under the sales agreement, the net proceeds to us and the compensation paid by us to Cowen in connection with the sales of common stock.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Settlement for sales of common stock will occur, unless the parties agree otherwise, on the third business day that is also a trading day following the date on which any sales were made in return for payment of the net proceeds to us.&nbsp;&nbsp;There is no arrangement for funds to be received in an escrow, trust or similar arrangement.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In connection with the sales of our common stock on our behalf, Cowen may be deemed to be an &#x201C;underwriter&#x201D; within the meaning of the Securities Act, and the compensation paid to Cowen may be deemed to be underwriting commissions or discounts.&nbsp;&nbsp;We have agreed in the sales agreement to provide indemnification and contribution to Cowen against certain liabilities, including liabilities under the Securities Act.&nbsp;&nbsp;As sales agent, Cowen will not engage in any transactions that stabilizes our common stock.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our common stock is listed on the Exchange and trades under the symbol &#x201C;GLYC.&#x201D;&nbsp;&nbsp;The transfer agent of our common stock is American Stock Transfer &amp; Trust Company.</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Cowen and/or its affiliates have provided, and may in the future provide, various investment banking and other financial services for us for which services they have received and, may in the future receive, customary fees.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-weight:bold;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">S-</font><font style="display:inline;">13</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;text-align:center;font-weight:bold;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">L</font><font style="display:inline;">EGA</font><a name="LEGAL_710258"></a><font style="display:inline;">L MATTERS</font>
		</p>
		<p style="margin:0pt;text-align:left;text-indent:18pt;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">T</font><font style="display:inline;">he validity of the </font><font style="display:inline;">common stock offered by this prospectus</font><font style="display:inline;"> supplement</font><font style="display:inline;">&nbsp;</font><font style="display:inline;">will be passed upon by Cooley LLP</font><font style="display:inline;">, Washington, District of Columbia</font><font style="display:inline;">.</font><font style="display:inline;">&nbsp;</font><font style="display:inline;color:#000000;">Goodwin Procter LLP</font><font style="display:inline;color:#000000;">, New York, New York</font><font style="display:inline;color:#000000;">&nbsp;</font><font style="display:inline;">is counsel for Cowen in connection with this offering. </font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-weight:bold;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">EX</font><a name="EXP_257999"></a><font style="display:inline;">PERTS</font>
		</p>
		<p style="margin:0pt;text-align:left;border-bottom:1pt none #D9D9D9 ;text-indent:18pt;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Ernst&nbsp;&amp; Young, LLP, independent registered accounting firm, has audited our financial statements at December&nbsp;31, </font><font style="display:inline;">2015</font><font style="display:inline;"> and 201</font><font style="display:inline;">4</font><font style="display:inline;">, and for the years then ended, as set forth in their report included in our Annual Report on </font><font style="text-decoration:none;text-decoration:none;display:inline;">Form 10-K</font><font style="display:inline;"> for the year ended December&nbsp;31, </font><font style="display:inline;">2015</font><font style="display:inline;">. Our financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#x2019;s report, given on their authority as experts in accounting and auditing</font><font style="display:inline;">.</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-weight:bold;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">WHERE YOU</font><a name="WHEREYOU_890137"></a><font style="display:inline;"> CAN FIND MORE INFORMATION</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">This prospectus</font><font style="display:inline;"> supplement and the accompanying prospectus are</font><font style="display:inline;"> part of a registration statement we filed with the SEC. This prospectus </font><font style="display:inline;">supplement and the accompanying prospectus do </font><font style="display:inline;">not contain all of the information set forth in the registration statement and the exhibits to the registration statement.&nbsp;&nbsp;For further information with respect to us and the securities we are offering under this prospectus</font><font style="display:inline;"> supplement</font><font style="display:inline;">, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement.&nbsp;&nbsp;Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus</font><font style="display:inline;"> supplement</font><font style="display:inline;"> is accurate as of any date other than the date on the front page of this prospectus</font><font style="display:inline;"> supplement</font><font style="display:inline;">, regardless of the time of delivery of this prospectus </font><font style="display:inline;">supplement </font><font style="display:inline;">or any sale of the securities offered by this prospectus</font><font style="display:inline;"> supplement</font><font style="display:inline;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement, as well as any other document filed by us with the SEC, at the SEC&#x2019;s Public Reference Room at 100 F Street NE, Washington, D.C. 20549. You can also request copies of these documents by writing to the SEC and paying a fee for the copying cost.&nbsp;&nbsp;You may obtain information on the operation of the Public Reference Room by calling the SEC at (800) SEC-0330. The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC, including </font><font style="display:inline;">GlycoMimetics, Inc</font><font style="display:inline;">. The address of the SEC website is www.sec.gov. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We maintain a website at www.</font><font style="display:inline;">glycomimetics</font><font style="display:inline;">.com. Information contained in or accessible through our website does not constitute a part of this prospectus</font><font style="display:inline;"> supplement or the accompanying prospectus</font><font style="display:inline;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-weight:bold;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">INCORPORATIO</font><a name="INCORPORATION_451608"></a><font style="display:inline;">N OF CERTAIN INFORMATION BY REFERENCE</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The SEC allows us to &#x201C;incorporate by reference&#x201D; information into this prospectus</font><font style="display:inline;"> supplement</font><font style="display:inline;">, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus</font><font style="display:inline;"> supplement</font><font style="display:inline;"> is 001-</font><font style="display:inline;">36177</font><font style="display:inline;">. The documents incorporated by reference into this prospectus</font><font style="display:inline;"> supplement</font><font style="display:inline;"> contain important information that you should read about us. </font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following documents are incorporated by reference into this document: </font>
		</p>
		<p style="margin:0pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">our Annual Report on Form 10-K for the fiscal year ended December 31, </font><font style="display:inline;color:#000000;">2015</font><font style="display:inline;color:#000000;"> filed with the SEC on </font><font style="display:inline;color:#000000;">February 29, 2016</font><font style="display:inline;color:#000000;">; &nbsp;</font><font style="display:inline;color:#000000;">and</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;text-indent: -18pt;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the description of our common stock, which is registered under Section 12 of the Exchange Act, in our registration statement on Form 8-A, filed with the SEC on</font><font style="display:inline;color:#000000;"> November 5</font><font style="display:inline;color:#000000;">, 2013, including any amendments or reports filed for the purpose of updating such description. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 72pt;text-indent: -36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We also incorporate by reference into this prospectus</font><font style="display:inline;"> supplement</font><font style="display:inline;"> all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus </font><font style="display:inline;">supplement </font><font style="display:inline;">but prior to the termination of the offering. These documents include periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements. </font>
		</p>
		<p style="margin:0pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">S-</font><font style="display:inline;">14</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus</font><font style="display:inline;"> supplement</font><font style="display:inline;"> but not delivered with th</font><font style="display:inline;">is</font><font style="display:inline;"> prospectus</font><font style="display:inline;"> supplement</font><font style="display:inline;">, including exhibits which are specifically incorporated by reference into such documents. Requests should be directed to: GlycoMimetics, Inc., Attn: Investor Relations, </font><font style="display:inline;">9708 Medical Center Drive, Rockville, Maryland 20850</font><font style="display:inline;">, telephone: (240)&nbsp;243-1201</font><font style="display:inline;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Any statement contained herein or in a document incorporated or deemed to be incorporated by reference into this document will be deemed to be modified or superseded for purposes of the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be incorporated by reference into this document modifies or supersedes the statement. </font>
		</p>
		<p style="margin:0pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">DISCLOSUR</font><a name="DISCLOSURE_463529"></a><font style="display:inline;font-weight:bold;">E OF COMMISSION&#x2019;S POSITION</font><font style="display:inline;font-weight:bold;"> ON INDEMNIFICATION FOR </font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">SECURITIES ACT LIABILITY</font><font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Company pursuant to the </font><font style="display:inline;">foregoing provisions</font><font style="display:inline;">, we have been informed that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. </font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">S-</font><font style="display:inline;">15</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-weight:bold;font-size:10pt;">PR</font><a name="PRO_599366"></a><font style="display:inline;font-weight:bold;font-size:10pt;">OSPECTUS </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"><img src="glyc20160301xs3001.jpg" style="width: 3.072917in; height: 0.6041667in" alt="Picture 4"></font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">$150,000,000 </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Common Stock </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Preferred Stock </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Debt Securities </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Warrants </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">From time to time, we may offer up to $150,000,000 of any combination of the securities described in this prospectus. We may also offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including any applicable antidilution provisions. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">This prospectus provides a general description of the securities we may offer. Each time we offer securities, we will provide specific terms of the securities offered in a supplement to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before you invest in any of the securities being offered. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">This prospectus may not be used to consummate a sale of any securities unless accompanied by a prospectus supplement. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Our common stock is traded on the Nasdaq Global Market under the symbol &#x201C;GLYC.&#x201D; On March&nbsp;16, 2015, the last reported sales price of our common stock was $8.21 per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing on the Nasdaq Global Market or any securities market or other exchange of the securities, if any, covered by the prospectus supplement. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We will sell these securities directly to investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section entitled &#x201C;Plan of Distribution&#x201D; in this prospectus. If any agents or underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts or over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="center"></hr></div>
		<p style="margin:0pt;text-indent:24.5pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#x201C;Risk Factors&#x201D; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="center"></hr></div>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. </font>
		</p>
		<div style="margin-top:12pt;"><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="center"></hr></div>
		<p style="margin:12pt 0pt 0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The date of this prospectus is</font><font style="display:inline;font-size:10pt;"> March 24, 2015</font><font style="display:inline;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-align:center;border-top:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:12pt 0pt 0pt;text-align:center;border-top:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">TABLE OF CONTENTS</font><a name="TABLEOFCONTENTS_638207"></a>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;text-align:justify;text-justify:inter-ideograph;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:97.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ABOUTTHISPROSPECTUS_642518"><font style="display:inline;">ABOUT THIS PROSPECTUS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.78%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">i</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:97.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#SUMMARY_183479"><font style="display:inline;">SUMMARY</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:02.78%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						1<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:97.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#RISKFACTORS_173839"><font style="display:inline;">RISK FACTORS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:02.78%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						6<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:97.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#SPECIALNOTEREGARDINGFORWARD_431950"><font style="display:inline;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:02.78%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						6<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:97.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#RATIOOFEARNINGS_880596"><font style="display:inline;">RATIO OF EARNINGS TO COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:02.78%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						7<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:97.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#USEOFPROCEEDS_36917"><font style="display:inline;">USE OF PROCEEDS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:02.78%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						8<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:97.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#DESCRIPTIONOFCAPITALSTOCK_875907"><font style="display:inline;">DESCRIPTION OF CAPITAL STOCK</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:02.78%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						8<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:97.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#DESCRIPTIONOFDEBTSECURITIES_898961"><font style="display:inline;">DESCRIPTION OF DEBT SECURITIES</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:02.78%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						12<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:97.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#DESCRIPTIONOFWARRANTS_237117"><font style="display:inline;">DESCRIPTION OF WARRANTS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:02.78%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						19<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:97.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#LEGALOWNERSHIPOFSECURITIES_320214"><font style="display:inline;">LEGAL OWNERSHIP OF SECURITIES</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:02.78%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						22<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:97.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#PLANOFDISTRIBUTION_606040"><font style="display:inline;">PLAN OF DISTRIBUTION</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:02.78%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						25<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:97.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#LEGALMATTERS_475625"><font style="display:inline;">LEGAL MATTERS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:02.78%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						27<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:97.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#EXPERT_376494"><font style="display:inline;">EXPERTS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:02.78%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						27<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:97.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#WHEREYOUCANFINDMORE_72570"><font style="display:inline;">WHERE YOU CAN FIND MORE INFORMATION</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:02.78%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						27<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:97.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#INCORPORATIONOFCERTAIN_434339"><font style="display:inline;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:02.78%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						27<font style="display:inline;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:97.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#DISCLOSUREOFCOMMISSIONPOSITION_515642"><font style="display:inline;">DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITY</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:02.78%;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						28<font style="display:inline;"></font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;text-align:center;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;text-align:center;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-weight:bold;font-size:10pt;">ABOUT THIS PROSPECTUS </font><a name="ABOUTTHISPROSPECTUS_642518"></a>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">This prospectus is a part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or SEC, utilizing a &#x201C;shelf&#x201D; registration process. Under this shelf registration process, we may sell any combination of the securities described in this prospectus in one or more offerings up to a total dollar amount of $150,000,000. This prospectus provides you with a general description of the securities we may offer. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Each time we sell securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus. You should read this prospectus, any applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the heading &#x201C;Incorporation of Certain Information By Reference,&#x201D; before investing in any of the securities offered. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">You should rely only on the information that we have provided or incorporated by reference in this prospectus, any applicable prospectus supplement and any related free writing prospectus that we may authorize to be provided to you. We have not authorized any dealer, salesman or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus that we may authorize to be provided to you. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus. This prospectus, any applicable supplement to this prospectus or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, any applicable supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">You should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered, or securities are sold, on a later date. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading &#x201C;Where You Can Find More Information.&#x201D; </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">i</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-weight:bold;font-size:10pt;">SUMMARY</font><a name="SUMMARY_183479"></a>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">This summary highlights selected information from this prospectus and does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the heading &#x201C;Risk Factors&#x201D; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Unless the context indicates otherwise, as used in this prospectus, the terms &#x201C;GlycoMimetics,&#x201D; &#x201C;the Company,&#x201D; &#x201C;we,&#x201D; &#x201C;us&#x201D; and &#x201C;our&#x201D; refer to GlycoMimetics, Inc., a Delaware corporation. We use GlycoMimetics and the GlycoMimetics logo as trademarks in the United States and other countries. All other trademarks or trade names referred to in this prospectus are the property of their respective owners. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Our Company </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We are a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using our expertise in carbohydrate chemistry and knowledge of carbohydrate biology, we are developing a pipeline of proprietary glycomimetics that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. We believe this represents an innovative approach to drug discovery to treat a wide range of diseases. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We are focusing our initial efforts on drug candidates for rare diseases that we believe will qualify for orphan drug designation. We are developing our lead drug candidate, rivipansel, formerly known as GMI-1070, for the treatment of vaso-occlusive crisis, or VOC, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. We have entered into a collaboration with Pfizer Inc. for the further development and potential commercialization of rivipansel worldwide. Rivipansel has received fast track designation from the U.S. Food and Drug Administration, or FDA, as well as orphan drug designation from the FDA in the United States and from the European Medicines Agency, or EMA, in the European Union, or EU. We believe the clinical progress of rivipansel provides evidence of the significant potential of our lead program and our proprietary glycomimetics platform. Building on our experience with rivipansel, we are developing our second most advanced drug candidate, GMI-1271, to be used in combination with chemotherapy to treat acute myeloid leukemia, or AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Our proprietary glycomimetics platform is based on our expertise in carbohydrate chemistry and our understanding of the role carbohydrates play in key biological processes. Most human proteins are modified by the addition of complex carbohydrates to the surface of the proteins. The addition of these carbohydrate structures affects the functions of these proteins and their interactions with other molecules. Our initial research and development efforts have focused on drug candidates targeting selectins, which are proteins that serve as adhesion molecules and bind to carbohydrates that are involved in the inflammatory component and progression of a wide range of diseases, including hematologic disorders, cancer and cardiovascular disease. For example, we believe that members of the selectin family play a key role in the onset and progression of VOC. Inhibiting specific carbohydrates from binding to selectins has long been viewed as a potentially attractive approach for therapeutic intervention. The ability to successfully develop drug-like compounds that inhibit binding with selectins, known as selectin antagonists, has been limited by the complexities of carbohydrate chemistry. We believe our expertise in carbohydrate chemistry and our understanding of carbohydrate-protein binding interactions enable us to design selectin antagonists and other glycomimetics that inhibit the disease-related functions of certain carbohydrates. We believe this expertise and knowledge enable us to develop novel drug candidates to address unmet medical needs. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">1</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">We are developing our lead drug candidate, rivipansel, to treat VOC. Rivipansel is a glycomimetic drug candidate that acts as a pan-selectin antagonist, meaning it binds to all three members of the selectin family, E-,&nbsp;P- and L-selectin. We believe that rivipansel, by acting as a pan-selectin antagonist, inhibits the role that selectins play in VOC. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Sickle cell disease is a genetic disease that, according to the U.S. Centers for Disease Control and Prevention, or CDC, affects millions of people throughout the world, including an estimated 90,000 to 100,000 people in the United States. VOC is one of the most severe complications of sickle cell disease. It can result in acute ischemic tissue injury at one or more sites, with inflammation and pain of varying degrees of severity. The standard of care in the United States for people experiencing VOC is to manage its symptoms, which typically includes hospitalization, narcotic pain management and hydration. There are no approved therapies that interrupt VOC once it has started or that treat the underlying cause of the pain. Hydroxyurea is a generic drug that is approved for the prevention of VOC, but it is not effective in the acute setting to relieve symptoms or resolve an ongoing VOC episode. In addition, hydroxyurea is not suitable for all patients and can have significant toxicities and side effects. According to the CDC, there were approximately 73,000 hospitalizations related to VOC in the United States in 2010. We believe that rivipansel, if approved, would be the first drug to interrupt the underlying cause of VOC, thereby potentially reducing the use of narcotics for pain management and enabling patients to leave the hospital more quickly. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We have completed four clinical trials of rivipansel involving a total of 163 subjects. In April 2013, we completed a Phase 2 clinical trial in which 76 patients hospitalized for VOC, ranging from 12 to 60 years old, were treated with the standard of care plus either rivipansel or placebo. In this trial, patients treated with rivipansel experienced reductions in the time to reach resolution of VOC, length of hospital stay and use of opioid analgesics for pain management, in each case as compared to patients receiving placebo. This improvement was seen in both adult and pediatric patients. Adverse event rates and severity were comparable between those treated with rivipansel and those receiving placebo. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We entered into a license agreement in October 2011 with Pfizer, under which Pfizer has rights to develop and commercialize rivipansel for all indications worldwide. Following the completion of our Phase 2 clinical trial, Pfizer is now responsible for the further clinical development, regulatory approval and potential commercialization of rivipansel. Under the Pfizer agreement, we received an upfront payment of $22.5 million from Pfizer. We are also eligible to receive payments of up to $115.0 million upon the achievement of specified development milestones, including the dosing of the first patients in Phase 3 clinical trials for up to two indications and the first commercial sale of a licensed product in the United States and selected European countries for up to two indications, up to $70.0 million upon the achievement of specified regulatory milestones, including the acceptance of our filings for review by regulatory authorities in the United States and Europe for up to two indications, and up to $135.0 million upon the achievement of specified levels of annual net sales of licensed products. We are also eligible to receive tiered royalties, with percentages ranging from the low double digits to the low teens, based on net sales of rivipansel worldwide, subject to reductions in specified circumstances. The first potential milestone payment under the Pfizer agreement was $35.0&nbsp;million upon the initiation of dosing of the first patient in a Phase 3 trial of rivipansel by Pfizer. Under the collaboration, Pfizer made a $15.0 million non-refundable payment to us in May 2014, and the dosing of the first patient in the Phase 3 clinical trial will trigger the remaining $20.0&nbsp;million milestone payment. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">In September 2014, we were informed by Pfizer that initiation of the Phase 3 clinical trial with rivipansel will be significantly delayed due to a manufacturing development issue impacting formulated drug supply. Pfizer advised us that the issue is under review and noted that upon identifying the specific cause and planned remedy of the manufacturing issue, they will inform us regarding a more specific timeframe for commencing the Phase 3 trial. Although Pfizer has taken and is taking a number of steps to prepare for Phase 3 initiation, including written agreement with the FDA under a special protocol assessment, or SPA, on the design of the planned Phase 3 trial, there can be no assurance that the conditions to Pfizer&#x2019;s obligation to make the remaining $20.0&nbsp;million milestone payment to us under the agreement will be satisfied. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Under a separate research agreement with the University of Basel, we have agreed to pay 10% of any future milestone payments and royalties we may receive from Pfizer with respect to rivipansel. As of December&nbsp;31, 2014, we accrued $1.5 million that is payable to the University, which is equal to 10% of the $15.0 million non-refundable milestone payment we received from Pfizer in May 2014. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">2</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">We are developing a pipeline of other drug candidates based on our expertise in carbohydrate chemistry, including compounds that are designed to be specific to particular selectins. We are developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with AML and potentially other hematologic cancers. E-selectin plays a critical role in binding cancer cells within vascular niches in the bone marrow, which prevents the cells from entering circulation where they can be more readily killed by chemotherapy. In animal studies, GMI-1271 mobilized AML cancer cells out of the bone marrow, making them more sensitive to chemotherapy. In these studies, tumor burden was significantly reduced in the animals treated with a combination of chemotherapy and GMI-1271 as compared to animals treated with chemotherapy alone. In addition, the combination of GMI-1271 with chemotherapy resulted in improved survival rates for the treated animals, compared to chemotherapy alone. In other animal studies, GMI-1271 appeared to also protect normal cells from some of the side effects of chemotherapy. Common side effects of chemotherapy include bone marrow toxicity resulting in neutropenia, which is an abnormally low number of neutrophils, the white blood cells that serve as the primary defense against infection, and mucositis, which is the inflammation and sloughing of the mucous membranes lining the digestive tract. Animals treated with GMI-1271 and chemotherapy had less severe neutropenia and mucositis and lower bone marrow toxicity as compared to animals treated with chemotherapy alone. We believe that treatment with GMI-1271 results in lower bone marrow toxicity due to its inhibition of E-selectin, which makes stem cells in the bone marrow divide less frequently, thereby protecting them from chemotherapy agents that target rapidly dividing cells. In December 2014, we presented preclinical data on GMI-1271 at the annual meeting of the American Society of Hematology. Based on our preclinical studies, we believe GMI-1271 may improve chemotherapy response rates, duration of remission and, ultimately, survival in patients with hematologic cancers like AML. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We held a pre-IND meeting with the FDA in November 2013 and filed an IND for GMI-1271 in February 2014. Following acceptance of the IND, we completed a Phase 1 single dose-escalation clinical trial in 28 healthy volunteers in August 2014. We have initiated preparations for a Phase 1/2 multiple dose-escalation clinical trial in defined populations of patients with AML, and we expect the patient recruitment for this trial to begin in the first quarter of 2015. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We have an additional drug candidate, GMI-1359, that simultaneously targets both E-selectin and a chemokine receptor known as CXCR4. GMI-1359 is currently undergoing testing in preclinical models from which we intend to select a target clinical indication, mostly likely in oncology. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">In addition to our programs described above, we are also advancing other preclinical-stage programs. These programs include a small-molecule glycomimetic compound, GMI-1051, that inhibits virulence factors and which we believe may be used for the treatment of Pseudomonas aeruginosa; a small-molecule glycomimetic compound that inhibits the protein galectin-3 that we believe may be used for the treatment of fibrosis, cancer and cardiovascular disease; and a small-molecule glycomimetic compound that inhibits the proteins galectin-1, -3 and -9 that we believe may be used for the treatment of cancer. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We have retained the worldwide development and commercialization rights to all of our drug candidates other than rivipansel. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Our intellectual property portfolio includes ownership of, or exclusive rights to, issued patents and pending patent applications claiming fundamental features of glycomimetic therapeutics, as well as those claiming methods of use for and chemical modifications of our drug candidates. Given the importance of our intellectual property portfolio to our business operations, we intend to vigorously enforce our rights and defend against challenges that have arisen or may arise in this area. Our issued patents directed to rivipansel and methods of use are expected to expire between 2023 and 2030, and our patent applications directed to GMI-1271, if issued, are expected to expire between 2032 and 2033. </font>
		</p>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">3</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;text-align:center;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-weight:bold;font-size:10pt;">Corporate Information </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We were incorporated under the laws of the State of Delaware in April 2003 and commenced operations in May 2003. Our principal executive offices are located at 401 Professional Drive, Suite 250, Gaithersburg, Maryland 20879. Our telephone number is (240)&nbsp;243-1201. Our website is located at http://www.glycomimetics.com. We do not incorporate by reference into this prospectus the information on, or accessible through, our website, and you should not consider it as part of this prospectus. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">The Securities We May Offer </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We may offer shares of our common stock and preferred stock, various series of debt securities and warrants to purchase any of such securities, with a total value of up to $150,000,000 from time to time under this prospectus, together with any applicable prospectus supplement and any related free writing prospectus, at prices and on terms to be determined by market conditions at the time of the offering. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable: </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">designation or classification; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">aggregate principal amount or aggregate offering price; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">maturity, if applicable; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">original issue discount, if any; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">rates and times of payment of interest or dividends, if any; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">redemption, conversion, exchange or sinking fund terms, if any; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">ranking; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">restrictive covenants, if any; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">voting or other rights, if any; and </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">important United States federal income tax considerations. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.55pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">4</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-weight:bold;font-size:10pt;">This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We may sell the securities directly to investors or through underwriters, dealers or agents. We, and our underwriters or agents, reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities through underwriters or agents, we will include in the applicable prospectus supplement: </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">the names of those underwriters or agents; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">applicable fees, discounts and commissions to be paid to them; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">details regarding over-allotment options, if any; and </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">the estimated net proceeds to us. </font></p></td></tr></table></div>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">Common Stock.</font><font style="display:inline;font-size:10pt;"> We may issue shares of our common stock from time to time. The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders and do not have cumulative voting rights. Subject to preferences that may be applicable to any outstanding shares of preferred stock, the holders of our common stock are entitled to receive ratably such dividends as may be declared by our board of directors out of legally available funds. Upon our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any then outstanding shares of preferred stock. Our common stock does not carry any preemptive rights enabling a holder to subscribe for, or receive shares of, any class of our common stock or any other securities convertible into shares of any class of our common stock, or any redemption rights. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">Preferred Stock.</font><font style="display:inline;font-size:10pt;"> We may issue shares of our preferred stock from time to time, in one or more series. Under our certificate of incorporation, our board of directors has the authority, without further action by the stockholders (unless such stockholder action is required by applicable law or the rules of any stock exchange or market on which our securities are then traded), to designate up to 5,000,000 shares of preferred stock in one or more series and to determine the designations, voting powers, preferences and rights of each series of the preferred stock, as well as the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, preemptive rights, terms of redemption or repurchase, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of any series, any or all of which may be greater than the rights of the common stock. Any convertible preferred stock we may issue will be convertible into our common stock or exchangeable for our other securities. Conversion may be mandatory or at the holder&#x2019;s option and would be at prescribed conversion rates. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">If we sell any series of preferred stock under this prospectus, we will fix the designations, voting powers, preferences and rights of such series of preferred stock, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock that we are offering before the issuance of the related series of preferred stock. We urge you to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of preferred stock being offered, as well as the complete certificate of designation that contains the terms of the applicable series of preferred stock. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">Debt Securities.</font><font style="display:inline;font-size:10pt;"> We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. The senior debt securities will rank equally with any other unsecured and unsubordinated debt. The subordinated debt securities will be subordinate and junior in right of payment, to the extent and in the manner described in the instrument governing the debt, to all of our senior indebtedness. Convertible debt securities will be convertible into or exchangeable for our common stock or preferred stock. Conversion may be mandatory or at the holder&#x2019;s option and would be at prescribed conversion rates. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The debt securities will be issued under one or more documents called indentures, which are contracts between us and a national banking association or other eligible party, as trustee. In this prospectus, we have summarized certain general </font><font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">5</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">features of the debt securities. We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of debt securities being offered, as well as the complete indentures that contain the terms of the debt securities. Forms of indentures have been filed as exhibits to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">Warrants. </font><font style="display:inline;font-size:10pt;">We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series. We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities. In this prospectus, we have summarized certain general features of the warrants. We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the particular series of warrants being offered, as well as the complete warrant agreements and warrant certificates that contain the terms of the warrants. Forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants being offered have been filed as exhibits to the registration statement of which this prospectus is a part, and supplemental warrant agreements and forms of warrant certificates will be filed as exhibits to the registration statement or will be incorporated by reference from reports that we file with the SEC. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We will evidence each series of warrants by warrant certificates that we will issue. Warrants may be issued under an applicable warrant agreement that we enter into with a warrant agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the particular series of warrants being offered. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">RISK FACTORS</font><a name="RISKFACTORS_173839"></a><font style="display:inline;font-weight:bold;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described under the heading &#x201C;Risk Factors&#x201D; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus, before deciding whether to purchase any of the securities being registered pursuant to the registration statement of which this prospectus is a part. Each of the risk factors could adversely affect our business, operating results and financial condition, as well as adversely affect the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment. Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair our business operations. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">SPECIAL NOTE REGARDING FORWAR</font><a name="SPECIALNOTEREGARDINGFORWARD_431950"></a><font style="display:inline;font-weight:bold;font-size:10pt;">D-LOOKING STATEMENTS</font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">This prospectus and the documents incorporated by reference contain forward-looking statements. These are based on our management&#x2019;s current beliefs, expectations and assumptions about future events, conditions and results and on information currently available to us. Discussions containing these forward-looking statements may be found, among other places, in the Sections entitled &#x201C;Business,&#x201D; &#x201C;Risk Factors&#x201D; and &#x201C;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201D; incorporated by reference from our most recent Annual Report on Form 10-K and in our Quarterly Reports on Form 10-Q, as well as any amendments thereto, filed with the SEC. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Any statements in this prospectus, or incorporated herein, about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. Within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Exchange Act, these forward-looking statements include, but are not limited to, statements regarding: </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">our plans to develop and commercialize our glycomimetic drug candidates; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 49pt;line-height:10pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">our planned clinical trials for our drug candidate GMI-1271; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 49pt;line-height:10pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">our ability to achieve anticipated milestones under our collaboration with Pfizer for our drug candidate rivipansel; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 49pt;line-height:10pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the timing of and our ability to obtain and maintain regulatory approvals for our drug candidates; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 49pt;line-height:10pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">6</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 0pt 49pt;line-height:10pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the clinical utility of our drug candidates; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 49pt;line-height:10pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">our commercialization, marketing and manufacturing capabilities and strategy; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 49pt;line-height:10pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">our intellectual property position; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 49pt;line-height:10pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">our ability to identify additional drug candidates with significant commercial potential that are consistent with our commercial objectives; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 49pt;line-height:10pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">our estimates regarding future revenues, expenses and needs for additional financing; and </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 49pt;line-height:10pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">our beliefs about our capital expenditure requirements and that our capital resources will be sufficient to meet our anticipated cash requirements through at least the next 12 months. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 49pt;line-height:10pt;text-indent: -24.5pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">In some cases, you can identify forward-looking statements by the words &#x201C;may,&#x201D; &#x201C;might,&#x201D; &#x201C;can,&#x201D; &#x201C;will,&#x201D; &#x201C;to be,&#x201D; &#x201C;could,&#x201D; &#x201C;would,&#x201D; &#x201C;should,&#x201D; &#x201C;expect,&#x201D; &#x201C;intend,&#x201D; &#x201C;plan,&#x201D; &#x201C;objective,&#x201D; &#x201C;anticipate,&#x201D; &#x201C;believe,&#x201D; &#x201C;estimate,&#x201D; &#x201C;predict,&#x201D; &#x201C;project,&#x201D; &#x201C;potential,&#x201D; &#x201C;likely,&#x201D; &#x201C;continue&#x201D; and &#x201C;ongoing,&#x201D; or the negative of these terms, or other comparable terminology intended to identify statements about the future, although not all forward-looking statements contain these words. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">You should refer to the &#x201C;Risk Factors&#x201D; section contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus, for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Given these risks, uncertainties and other factors, many of which are beyond our control, we cannot assure you that the forward-looking statements in this prospectus will prove to be accurate, and you should not place undue reliance on these forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to revise any forward-looking statements to reflect events or developments occurring after the date of this prospectus, even if new information becomes available in the future. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">RATIO OF EARNINGS</font><a name="RATIOOFEARNINGS_880596"></a><font style="display:inline;font-weight:bold;font-size:10pt;"> TO COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The following table sets forth our ratio of earnings to fixed charges and the ratio of earnings to combined fixed charges and preference securities dividends for each of the periods indicated. The following table is qualified by the more detailed information appearing in the computation table set forth in Exhibit 12.1 to the registration statement of which this prospectus is part and our historical financial statements, including the notes to those financial statements, incorporated by reference in this prospectus. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;background-color: #FFFFFF;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:58.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 7.2pt;height:1.00pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 7.2pt;height:1.00pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 7.2pt;height:1.00pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 7.2pt;height:1.00pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 7.2pt;height:1.00pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 7.2pt;height:1.00pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:00.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.18%;background-color: #FFFFFF;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-bottom:1pt solid #000000 ;background-color: #FFFFFF;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">Year</font><br /><font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">Ended</font><br /><font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.40%;border-bottom:1pt solid #000000 ;background-color: #FFFFFF;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">Year</font><br /><font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">Ended</font><br /><font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">2013</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-bottom:1pt solid #000000 ;background-color: #FFFFFF;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">Year</font><br /><font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">Ended</font><br /><font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">2012</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.40%;border-bottom:1pt solid #000000 ;background-color: #FFFFFF;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">Year</font><br /><font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">Ended</font><br /><font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">2011</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.40%;border-bottom:1pt solid #000000 ;background-color: #FFFFFF;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">Year</font><br /><font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">Ended</font><br /><font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">2010</font></p>
				</td>
				<td valign="bottom" style="width:00.24%;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Ratio of earnings to combined fixed charges and preferred stock dividends</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">deficiency</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.40%;border-top:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">deficiency</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">N/A</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.40%;border-top:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">deficiency</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.40%;border-top:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">deficiency</font></p>
				</td>
				<td valign="bottom" style="width:00.24%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.18%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Deficiency (in thousands) ($)</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.28%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,122)
				</td>
				<td valign="bottom" style="width:00.96%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.40%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(10,606)
				</td>
				<td valign="bottom" style="width:00.96%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.28%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">N/A</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.40%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,113)
				</td>
				<td valign="bottom" style="width:00.96%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.40%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,382)
				</td>
				<td valign="bottom" style="width:00.24%;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:10pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We did not record earnings for the years ended December&nbsp;31, 2014, 2013, 2011 and 2010 presented in the above table. Accordingly, our earnings were inadequate to cover fixed charges and preferred stock dividends for each such period. The amount of the deficiency by which our earnings did not cover our fixed charges and preferred stock </font><font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">7</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">dividends for each such period is disclosed in the second line of the above table, in thousands of dollars. For the year ending December&nbsp;31, 2012, we recorded earnings of $3.6 million; however, there were no fixed charges or preferred stock dividends for the year. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">USE OF PROCEEDS </font><a name="USEOFPROCEEDS_36917"></a>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. Except as described in any applicable prospectus supplement or in any free writing prospectuses that we may authorize to be provided to you in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered hereby to conduct planned clinical trials of GMI-1271, to fund the research and development of our preclinical pipeline, including drug discovery, and for working capital and other general corporate purposes. We may also use a portion of the net proceeds to invest in or acquire businesses or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus. We will set forth in the applicable prospectus supplement or free writing prospectus our intended use for the net proceeds received from the sale of any securities sold pursuant to the prospectus supplement or free writing prospectus. Pending these uses, we intend to invest the net proceeds in investment-grade, interest-bearing securities. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">DESCRIPTION OF CAPITAL STOCK </font><a name="DESCRIPTIONOFCAPITALSTOCK_875907"></a>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">As of the date of this prospectus, our certificate of incorporation authorizes us to issue 100,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share. As of December&nbsp;31, 2014, 18,939,838 shares of common stock were outstanding and no shares of preferred stock were outstanding. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The following summary description of our capital stock is based on the provisions of our certificate of incorporation, as well as our bylaws and the applicable provisions of the Delaware General Corporation Law. This information is qualified entirely by reference to the applicable provisions of our certificate of incorporation, bylaws and the Delaware General Corporation Law. For information on how to obtain copies of our certificate of incorporation and bylaws, which are exhibits to the registration statement of which this prospectus is a part, see &#x201C;Where You Can Find Additional Information.&#x201D; </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Common Stock </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders. The holders of our common stock do not have cumulative voting rights in the election of directors. Subject to preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably such dividends as may be declared by our board of directors out of legally available funds. Upon our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any outstanding shares of preferred stock. Holders of common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to our common stock. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Additional shares of authorized common stock may be issued, as authorized by our board of directors from time to time, without stockholder approval, except as may be required by applicable stock exchange requirements. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The rights of the holders of our common stock are subject to, and may be adversely affected by, the rights of holders of shares of any preferred stock that we may designate and issue in the future. </font>
		</p>
		<p style="margin:0pt 0pt 0pt 24.45pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Registration Rights </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We and the some of the holders of our common stock have entered into an investor rights agreement. The registration rights provisions of this agreement provide those holders with demand, piggyback and Form S-3 registration rights with respect to the shares of our common stock currently held by them. </font>
		</p>
		<p style="margin:0pt 0pt 0pt 24.45pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 24.45pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">8</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 0pt 24.45pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-style:italic;font-size:10pt;">Demand Registration Rights </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The holders of at least 40% of the shares held by the parties to the investor rights agreement have the right to demand that we file up to a total of two registration statements, as long as the anticipated aggregate offering price, net of underwriting discounts and commissions, would exceed $10.0 million. These registration rights are subject to specified conditions and limitations, including the right of the underwriters, if any, to limit the number of shares included in any such registration under specified circumstances. Upon such a request, we are required to effect the registration as soon as reasonably possible. </font>
		</p>
		<p style="margin:0pt 0pt 0pt 24.45pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 24.45pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;font-size:10pt;">Piggyback Registration Rights </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">If we propose to register any of our securities under the Securities Act either for our own account or for the account of other stockholders, the parties to the investor rights agreement with piggyback registration rights will each be entitled to notice of the registration and will be entitled to include their shares of common stock in the registration statement. These piggyback registration rights are subject to specified conditions and limitations, including the right of the underwriters to limit the number of shares included in any such registration under specified circumstances. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Pursuant to the terms of our currently outstanding warrant to purchase common stock held by a prior lender, the holder has similar piggyback registration rights with respect to the shares of our common stock issuable upon exercise of the warrant. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;font-size:10pt;">Registration on Form S-3 </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">If we are eligible to file a registration statement on Form S-3, the parties to the investor rights agreement are entitled, upon their written request, to have such shares registered by us on a Form S-3 registration statement at our expense, provided that such requested registration has an anticipated aggregate offering size to the public of at least $1.0 million and subject to other specified conditions and limitations. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;font-size:10pt;">Expenses of Registration </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We will pay all expenses relating to any demand, piggyback or Form S-3 registration, other than underwriting discounts and commissions, subject to specified conditions and limitations. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;font-size:10pt;">Termination of Registration Rights </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The registration rights granted under the investor rights agreement will terminate upon the seventh anniversary of the completion of our initial public offering, which would be in January 2021, or, if earlier, with respect to a particular holder, at such time as that holder and its affiliates may sell all of their shares of common stock pursuant to Rule 144 under the Securities Act of 1933, as amended, without any restrictions on volume. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Preferred Stock </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Pursuant to our amended and restated certificate of incorporation, or the Restated Certificate, our board of directors has the authority, without further action by the stockholders (unless such stockholder action is required by applicable law or stock exchange listing rules), to designate and issue up to 5,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the designations, powers, preferences, privileges and relative participating, optional or special rights and the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, voting rights, terms of redemption and liquidation preferences, any or all of which may be greater than the rights of the common stock, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The board of directors, without stockholder approval, can issue preferred stock with voting, conversion or other rights that could adversely affect the voting power and other rights of the holders of common stock. Preferred stock could be issued quickly with terms designed to delay or prevent a change in control of our company or make removal of management more difficult. Additionally, the issuance of preferred stock may have the effect of decreasing the market </font><font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">9</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">price of the common stock and may adversely affect the voting power of holders of common stock and reduce the likelihood that common stockholders will receive dividend payments and payments upon liquidation. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Our board of directors will fix the designations, voting powers, preferences and rights of the each series, as well as the qualifications, limitations or restrictions thereof, of the preferred stock of each series that we offer under this prospectus and applicable prospectus supplements in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of that series of preferred stock. This description will include: </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the title and stated value; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the number of shares we are offering; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the liquidation preference per share; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the purchase price per share; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the dividend rate per share, dividend period and payment dates and method of calculation for dividends; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">our right, if any, to defer payment of dividends and the maximum length of any such deferral period; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the procedures for any auction and remarketing, if any; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the provisions for a sinking fund, if any; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">any listing of the preferred stock on any securities exchange or market; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">whether the preferred stock will be convertible into our common stock or other securities of ours, including depositary shares and warrants, and, if applicable, the conversion period, the conversion price, or how it will be calculated, and under what circumstances it may be adjusted; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange period, the exchange price, or how it will be calculated, and under what circumstances it may be adjusted; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">voting rights, if any, of the preferred stock; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">preemption rights, if any; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">restrictions on transfer, sale or other assignment, if any; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">whether interests in the preferred stock will be represented by depositary shares; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">a discussion of any material or special United States federal income tax considerations applicable to the preferred stock; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">10</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">any limitations on issuances of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock being issued as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">any other specific terms, rights, preferences, privileges, qualifications or restrictions of the preferred stock. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The General Corporation Law of the State of Delaware, the state of our incorporation, provides that the holders of preferred stock will have the right to vote separately as a class (or, in some cases, as a series) on an amendment to our certificate of incorporation if the amendment would change the par value or, unless the certificate of incorporation provided otherwise, the number of authorized shares of the class or change the powers, preferences or special rights of the class or series so as to adversely affect the class or series, as the case may be. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation. </font>
		</p>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Antitakeover Effects of Provisions of Charter Documents and Delaware Law </font>
		</p>
		<p style="margin:0pt;line-height:10pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;font-size:10pt;">Charter Documents.</font><font style="display:inline;font-size:10pt;"> Our Restated Certificate and Amended and Restated Bylaws, or Bylaws, each as amended to date, include a number of provisions that may have the effect of deterring hostile takeovers or delaying or preventing changes in control or management of our company. First, our board of directors is classified into three classes of directors. Under Delaware law, directors of a corporation with a classified board may be removed only for cause unless the corporation&#x2019;s certificate of incorporation provides otherwise. Our Restated Certificate does not provide otherwise. In addition, the Restated Certificate provides that all stockholder action must be effected at a duly called meeting of stockholders and not by a consent in writing. Further, our Bylaws limit who may call special meetings of the stockholders. Our Restated Certificate does not include a provision for cumulative voting for directors. Under cumulative voting, a minority stockholder holding a sufficient percentage of a class of shares may be able to ensure the election of one or more directors. Finally, our Bylaws establish procedures, including advance notice procedures, with regard to the nomination of candidates for election as directors and stockholder proposals. These and other provisions of our Restated Certificate and Bylaws and Delaware law could discourage potential acquisition proposals and could delay or prevent a change in control or management of our company. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;font-size:10pt;">Delaware Takeover Statute. </font><font style="display:inline;font-size:10pt;">We are subject to Section&nbsp;203 of the General Corporation Law of the State of Delaware, or DGCL, which regulates acquisitions of some Delaware corporations. Section&nbsp;203 generally prohibits a publicly held Delaware corporation from engaging in a &#x201C;business combination&#x201D; with an &#x201C;interested stockholder&#x201D; for a period of three years following the date of the transaction in which the person became an interested stockholder, unless: </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the board of directors of the corporation approved the business combination or the other transaction in which the person became an interested stockholder prior to the date of the business combination or other transaction; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">upon consummation of the transaction that resulted in the person becoming an interested stockholder, the person owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding shares owned by persons who are directors and also officers of the corporation and shares issued under employee stock plans under which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">on or subsequent to the date the person became an interested stockholder, the board of directors of the corporation approved the business combination and the stockholders of the corporation authorized the business combination at an annual or special meeting of stockholders by the affirmative vote of at least 66-2/3% of the outstanding stock of the corporation not owned by the interested stockholder. </font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">11</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;text-indent:24.5pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">Section&nbsp;203 of the DGCL defines a &#x201C;business combination&#x201D; to include any of the following: </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">any merger or consolidation involving the corporation and the interested stockholder; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">any sale, transfer, pledge or other disposition of 10% or more of the corporation&#x2019;s assets or outstanding stock involving the interested stockholder; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any of its stock to the interested stockholder; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">any transaction involving the corporation that has the effect of increasing the proportionate share of its stock owned by the interested stockholder; or </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.55pt;text-indent: -24.5pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">In general, Section&nbsp;203 defines an &#x201C;interested stockholder&#x201D; as any person who, together with the person&#x2019;s affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#x2019;s voting stock. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Section&nbsp;203 of the DGCL could depress our stock price and delay, discourage or prohibit transactions not approved in advance by our board of directors, such as takeover attempts that might otherwise involve the payment to our stockholders of a premium over the market price of our common stock. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Transfer Agent And Registrar </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The transfer agent and registrar for our common stock is American Stock Transfer&nbsp;&amp; Trust Company, and its address is 6201 15th Street, Brooklyn, NY 11219. The transfer agent for any series of preferred stock that we may offer under this prospectus will be named and described in the prospectus supplement for that series. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Listing on the Nasdaq Global Market </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Our common stock is listed on the Nasdaq Global Market under the symbol &#x201C;GLYC.&#x201D; </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">DESCRIPTION OF DEBT SECURITIES </font><a name="DESCRIPTIONOFDEBTSECURITIES_898961"></a>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to any supplemental indentures that specify the terms of a particular series of debt securities. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We will issue the debt securities under the indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act. We have filed the form of indenture as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The following summary of material provisions of the debt securities and the indentures is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements and any related free writing prospectuses related to the debt </font><font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">12</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">General </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The indenture does not limit the amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the limitations on consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities protection against changes in our operations, financial condition or transactions involving us. </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We may issue the debt securities issued under the indenture as &#x201C;discount securities,&#x201D; which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &#x201C;original issue discount,&#x201D; or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be described in more detail in any applicable prospectus supplement. </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We will describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including: </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the title of the series of debt securities; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">any limit upon the aggregate principal amount that may be issued; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the maturity date or dates; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the form of the debt securities of the series; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the applicability of any guarantees; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms of any subordination; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt securities that is convertible into another security or the method by which any such portion shall be determined; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">our right, if any, to defer payment of interest and the maximum length of any such deferral period; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions; </font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">13</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#x2019;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or securities; the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities; and the depositary for such global security or securities; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the holders&#x2019; option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the series which shall be payable upon declaration of acceleration of the maturity thereof; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">additions to or changes in the covenants applicable to the particular debt securities being issued, including, among others, the consolidation, merger or sale covenant; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">additions to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">additions to or changes in the provisions relating to satisfaction and discharge of the indenture; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">additions to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of debt securities issued under the indenture; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">whether interest will be payable in cash or additional debt securities at our or the holders&#x2019; option and the terms and conditions upon which the election may be made; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any and principal amounts of the debt securities of the series to any holder that is not a &#x201C;United States person&#x201D; for federal tax purposes; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">14</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">any restrictions on transfer, sale or assignment of the debt securities of the series; and </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.55pt;text-indent: -24.5pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Conversion or Exchange Rights </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We will set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities. We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of debt securities receive would be subject to adjustment. </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Consolidation, Merger or Sale </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets (other than a subsidiary of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Events of Default under the Indenture </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indenture with respect to any series of debt securities that we may issue: </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become due and payable, and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of interest for this purpose; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90&nbsp;days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">if specified events of bankruptcy, insolvency or reorganization occur. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.55pt;text-indent: -24.5pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">If an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the principal amount </font><font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">15</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder. </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default. </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Subject to the terms of the indenture, if an event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that: </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the direction so given by the holder is not in conflict with any law or the applicable indenture; and </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.55pt;text-indent: -24.5pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">A holder of the debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only if: </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the holder has given written notice to the trustee of a continuing event of default with respect to that series; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request, </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities to be incurred by the trustee in compliance with the request; and </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within 90&nbsp;days after the notice, request and offer. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.55pt;text-indent: -24.5pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities. </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We will periodically file statements with the trustee regarding our compliance with specified covenants in the indenture. </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Modification of Indenture; Waiver </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We and the trustee may change an indenture without the consent of any holders with respect to specific matters: </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">to comply with the provisions described above under &#x201C;Description of Debt Securities&#x2014;Consolidation, Merger or Sale;&#x201D; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">to provide for uncertificated debt securities in addition to or in place of certificated debt securities; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">16</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred upon us in the indenture; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">to make any change that does not adversely affect the interests of any holder of debt securities of any series in any material respect; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided above under &#x201C;Description of Debt Securities&#x2014;General&#x201D; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.55pt;text-indent: -24.5pt;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected: </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">extending the fixed maturity of any debt securities of any series; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption of any series of any debt securities; or </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 55.05pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Discharge </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Each indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations to: </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">provide for payment; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">register the transfer or exchange of debt securities of the series; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">replace stolen, lost or mutilated debt securities of the series; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">pay principal of and premium and interest on any debt securities of the series; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">maintain paying agencies; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">17</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">hold monies for payment in trust; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">recover excess money held by the trustee; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">compensate and indemnify the trustee; and </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">appoint any successor trustee. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">In order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due. </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Form, Exchange and Transfer </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We will issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company, or DTC, or another depositary named by us and identified in the applicable prospectus supplement with respect to that series. To the extent the debt securities of a series are issued in global form and as book-entry, a description of terms relating to any book-entry securities will be set forth in the applicable prospectus supplement. </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges. </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">If we elect to redeem the debt securities of any series, we will not be required to: </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15&nbsp;days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 80.6pt;text-indent: -25.9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part. </font></p></td></tr></table></div>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">18</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-weight:bold;font-size:10pt;">Information Concerning the Trustee </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Payment and Paying Agents </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series. </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Governing Law </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The indenture and the debt securities will be governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust Indenture Act of 1939 is applicable. </font>
		</p>
		<p style="margin:0pt;text-indent:48.95pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">DESCRIPTION OF WARRANTS </font><a name="DESCRIPTIONOFWARRANTS_237117"></a>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The following description, together with the additional information we may include in any applicable prospectus supplements and free writing prospectuses, summarizes the material terms and provisions of the warrants that we may issue under this prospectus, which may consist of warrants to purchase common stock, preferred stock or debt securities and may be issued in one or more series. Warrants may be issued independently or together with common stock, preferred stock or debt securities offered by any prospectus supplement, and may be attached to or separate from those securities. While the terms we have summarized below will apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants that we may offer in more detail in the applicable prospectus supplement and any applicable free writing prospectus. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We have filed forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants being offered as exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant agreement, if any, including a form of warrant certificate, that describes the terms of the particular series of warrants we are offering before the issuance of the related series of warrants. The following summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to the particular </font><font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">19</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">series of warrants that we may offer under this prospectus. We urge you to read the applicable prospectus supplements related to the particular series of warrants that we may offer under this prospectus, as well as any related free writing prospectuses, and the complete warrant agreements and warrant certificates that contain the terms of the warrants. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">General </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We will describe in the applicable prospectus supplement the terms relating to a series of warrants being offered, including: </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">the offering price and aggregate number of warrants offered; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 105.1pt;text-indent: -25.9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">the currency for which the warrants may be purchased; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 105.1pt;text-indent: -25.9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 105.1pt;text-indent: -25.9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">if applicable, the date on and after which the warrants and the related securities will be separately transferable; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 105.1pt;text-indent: -25.9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at which, and currency in which, this principal amount of debt securities may be purchased upon such exercise; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 105.1pt;text-indent: -25.9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which, and the currency in which, these shares may be purchased upon such exercise; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 105.1pt;text-indent: -25.9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 105.1pt;text-indent: -25.9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">the terms of any rights to redeem or call the warrants; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 105.1pt;text-indent: -25.9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">the terms of any rights to force the exercise of the warrants; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 105.1pt;text-indent: -25.9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 105.1pt;text-indent: -25.9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">the dates on which the right to exercise the warrants will commence and expire; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 105.1pt;text-indent: -25.9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">the manner in which the warrant agreements and warrants may be modified; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 105.1pt;text-indent: -25.9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">a discussion of any material or special United States federal income tax consequences of holding or exercising the warrants; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 105.1pt;text-indent: -25.9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">the terms of the securities issuable upon exercise of the warrants; and </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 105.1pt;text-indent: -25.9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">any other specific terms, preferences, rights or limitations of or restrictions on the warrants. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 104pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">20</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including: </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 105.1pt;text-indent: -25.9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 104pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Exercise of Warrants </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants by delivering the warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to the warrant agent in connection with the exercise of the warrant. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Upon receipt of the required payment and the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised, then we will issue a new warrant certificate for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Governing Law </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Unless we provide otherwise in the applicable prospectus supplement, the warrants and warrant agreements will be governed by and construed in accordance with the laws of the State of New York. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Enforceability of Rights by Holders of Warrants </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Outstanding Warrants to Purchase Common Stock </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">As of December&nbsp;31, 2014, we had outstanding warrants to purchase 589,051 shares of common stock at an exercise price of $0.33 per share, which warrants expire between December 2015 and January 2019, and warrants to purchase 1,544 shares of common stock at an exercise price of $25.92, which warrants expire in October 2016. The </font><font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">21</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">number of shares of Common Stock issuable upon the exercise of each warrant is subject to adjustment from time to time upon the occurrence of specified events. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">LEGAL OWNERSHIP OF SECURITIES </font><a name="LEGALOWNERSHIPOFSECURITIES_320214"></a>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee or depositary maintain for this purpose as the &#x201C;holders&#x201D; of those securities. These persons are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#x201C;indirect holders&#x201D; of those securities. As we discuss below, indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Book-Entry Holders </font>
		</p>
		<p style="margin:0pt;line-height:10pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary&#x2019;s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Only the person in whose name a security is registered is recognized as the holder of that security. Global securities will be registered in the name of the depositary or its participants. Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with their customers; they are not obligated to do so under the terms of the securities. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">As a result, investors in a global security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary&#x2019;s book-entry system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Street Name Holders </font>
		</p>
		<p style="margin:0pt;line-height:10pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We may terminate a global security or issue securities that are not issued in global form. In these cases, investors may choose to hold their securities in their own names or in &#x201C;street name.&#x201D; Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">For securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as the holders of those securities, and we or any such trustee or depositary will make all payments on those securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not holders, of those securities. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Legal Holders </font>
		</p>
		<p style="margin:0pt;line-height:10pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Our obligations, as well as the obligations of any applicable trustee or third party employed by us or a trustee, run only to the legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">For example, once we make a payment or give a notice to the holder, we have no further responsibility for the payment or notice even if that holder is required, under agreements with its participants or customers or by law, to pass it </font><font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">22</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">along to the indirect holders but does not do so. Similarly, we may want to obtain the approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of an indenture, or for other purposes. In such an event, we would seek approval only from the legal holders, and not the indirect holders, of the securities. Whether and how the holders contact the indirect holders is up to the legal holders. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Special Considerations for Indirect Holders </font>
		</p>
		<p style="margin:0pt;line-height:10pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">If you hold securities through a bank, broker or other financial institution, either in book-entry form because the securities are represented by one or more global securities or in street name, you should check with your own institution to find out: </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">how it handles securities payments and notices; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 80.6pt;line-height:10pt;text-indent: -25.9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">whether it imposes fees or charges; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 80.6pt;line-height:10pt;text-indent: -25.9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">how it would handle a request for the holders&#x2019; consent, if ever required; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 80.6pt;line-height:10pt;text-indent: -25.9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted in the future; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 80.6pt;line-height:10pt;text-indent: -25.9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests; and </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 80.6pt;line-height:10pt;text-indent: -25.9pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:8pt;"><p style="width:8pt;width:8pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">if the securities are in book-entry form, how the depositary&#x2019;s rules and procedures will affect these matters. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Global Securities </font>
		</p>
		<p style="margin:0pt;line-height:10pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Each security issued in book-entry form will be represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, The Depository Trust Company, New York, New&nbsp;York, known as DTC, will be the depositary for all securities issued in book-entry form. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We describe those situations below under &#x201C;&#x2014;Special Situations When A Global Security Will Be Terminated.&#x201D; As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the security, but only an indirect holder of a beneficial interest in the global security. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">If the prospectus supplement for a particular security indicates that the security will be issued as a global security, then the security will be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Special Considerations For Global Securities </font>
		</p>
		<p style="margin:0pt;line-height:10pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">As an indirect holder, an investor&#x2019;s rights relating to a global security will be governed by the account rules of the investor&#x2019;s financial institution and of the depositary, as well as general laws relating to securities transfers. We do not </font><font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">23</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">If securities are issued only as global securities, an investor should be aware of the following: </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">an investor cannot cause the securities to be registered in his or her name, and cannot obtain non-global certificates for his or her interest in the securities, except in the special situations we describe below; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in non-book-entry form; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">an investor may not be able to pledge his or her interest in the global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">the depositary&#x2019;s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor&#x2019;s interest in the global security; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">we and any applicable trustee have no responsibility for any aspect of the depositary&#x2019;s actions or for its records of ownership interests in the global security, nor will we or any applicable trustee supervise the depositary in any way; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in the global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well; and </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">financial institutions that participate in the depositary&#x2019;s book-entry system, and through which an investor holds its interest in the global security, may also have their own policies affecting payments, notices and other matters relating to the securities. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries. </font>
		</p>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Special Situations When A Global Security Will Be Terminated </font>
		</p>
		<p style="margin:0pt;line-height:10pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">In a few special situations described below, a global security will terminate and interests in it will be exchanged for physical certificates representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in securities transferred to their own names, so that they will be direct holders. We have described the rights of holders and street name investors above. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">A global security will terminate when the following special situations occur: </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90 days; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">if we notify any applicable trustee that we wish to terminate that global security; or </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 79.2pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">24</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">The applicable prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular series of securities covered by the prospectus supplement. When a global security terminates, the depositary, and neither we nor any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">PLAN OF DISTRIBUTION</font><a name="PLANOFDISTRIBUTION_606040"></a><font style="display:inline;font-weight:bold;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions: </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">at a fixed price or prices, which may be changed; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 103.7pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">at market prices prevailing at the time of sale; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 103.7pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">at prices related to such prevailing market prices; or </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 103.7pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">at negotiated prices. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 103.7pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We may also sell equity securities covered by this registration statement in an &#x201C;at the market offering&#x201D; as defined in Rule 415 under the Securities Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price, either: </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">on or through the facilities of the Nasdaq Global Market or any other securities exchange or quotation or trading service on which such securities may be listed, quoted or traded at the time of sale; and/or </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 103.7pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">to or through a market maker otherwise than on the Nasdaq Global Market or such other securities exchanges or quotation or trading services. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 103.7pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Such at-the-market offerings, if any, may be conducted by underwriters acting as principal or agent. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities, including, to the extent applicable: </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">the name or names of any underwriters, if any; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 103.7pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">the purchase price of the securities and the proceeds we will receive from the sale; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 103.7pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">any over-allotment options under which underwriters may purchase additional securities from us; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 103.7pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">any agency fees or underwriting discounts and other items constituting agents&#x2019; or underwriters&#x2019; compensation; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 103.7pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">any public offering price; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 103.7pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">any discounts or concessions allowed or reallowed or paid to dealers; and </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 103.7pt;line-height:10pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">any securities exchange or market on which the securities may be listed. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 104pt;text-indent: -24.5pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Only underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public offering price or at varying prices determined at </font><font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">25</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities, and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of its appointment. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We may provide agents and underwriters with indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">All securities we offer, other than common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Any underwriters who are qualified market makers on the Nasdaq Global Market may engage in passive market making transactions in the securities on the Nasdaq Global Market in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker&#x2019;s bid, however, the passive market maker&#x2019;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">In compliance with guidelines of the Financial Industry Regulatory Authority, or FINRA, the maximum consideration or discount to be received by any FINRA member or independent broker dealer may not exceed 8% of the aggregate amount of the securities offered pursuant to this prospectus and any applicable prospectus supplement. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">26</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-weight:bold;font-size:10pt;">LEGAL MATTERS </font><a name="LEGALMATTERS_475625"></a>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Unless otherwise indicated in the applicable prospectus supplement, certain legal matters in connection with the offering and the validity of the securities offered by this prospectus, and any supplement thereto, will be passed upon by Cooley LLP. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">EXPER</font><a name="EXPERT_376494"></a><font style="display:inline;font-weight:bold;font-size:10pt;">TS </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Ernst&nbsp;&amp; Young, LLP, independent registered accounting firm, has audited our financial statements at December&nbsp;31, 2014 and 2013, and for the years then ended, as set forth in their report included in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2014. Our financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#x2019;s report, given on their authority as experts in accounting and auditing. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">WHERE YOU CAN FIND MORE</font><a name="WHEREYOUCANFINDMORE_72570"></a><font style="display:inline;font-weight:bold;font-size:10pt;"> INFORMATION </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">This prospectus is part of a registration statement we filed with the Securities and Exchange Commission, or SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated by reference. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement, as well as any other document filed by us with the SEC, at the SEC&#x2019;s Public Reference Room at 100 F Street NE, Washington, D.C. 20549. You can also request copies of these documents by writing to the SEC and paying a fee for the copying cost. You may obtain information on the operation of the Public Reference Room by calling the SEC at (800)&nbsp;SEC-0330. The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC, including GlycoMimetics. The address of the SEC website is </font><font style="display:inline;font-size:10pt;">www.sec.gov</font><font style="display:inline;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We maintain a website at www.glycomimetics.com. Information contained in or accessible through our website does not constitute a part of this prospectus. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">INCORPORATION OF CERTAIN</font><a name="INCORPORATIONOFCERTAIN_434339"></a><font style="display:inline;font-weight:bold;font-size:10pt;"> INFORMATION BY REFERENCE </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The SEC allows us to &#x201C;incorporate by reference&#x201D; information into this prospectus, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus is 001-36177. The documents incorporated by reference into this prospectus contain important information that you should read about us. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The following documents are incorporated by reference into this document: </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2014 and filed with the SEC on March&nbsp;16, 2015; and </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 103.7pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:79pt;"><p style="width:79pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;text-align:left;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:7pt;"><p style="width:7pt;width:7pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-size:10pt;color:#000000;">the description of our common stock, which is registered under Section&nbsp;12 of the Exchange Act, in our registration statement on Form 8-A, filed with the SEC on November&nbsp;5, 2013, including any amendments or reports filed for the purpose of updating such description. </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 104pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item&nbsp;2.02 or Item&nbsp;7.01 of Form 8-K and exhibits filed on such form that are related to such items) that are filed by us </font><font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">27</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;">with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i)&nbsp;after the date of the initial filing of the registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement, or (ii)&nbsp;after the date of this prospectus but prior to the termination of the offering. These documents include periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits which are specifically incorporated by reference into such documents. Requests should be directed to: GlycoMimetics, Inc., Attn: Investor Relations, 401 Professional Drive, Suite 250, Gaithersburg, Maryland 20879, telephone: (240)&nbsp;243-1201. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Any statement contained herein or in a document incorporated or deemed to be incorporated by reference into this document will be deemed to be modified or superseded for purposes of the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be incorporated by reference into this document modifies or supersedes the statement. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">DISCLOSURE OF COMMISSION POSITIO</font><a name="DISCLOSUREOFCOMMISSIONPOSITION_515642"></a><font style="display:inline;font-weight:bold;font-size:10pt;">N ON INDEMNIFICATION FOR&nbsp;SECURITIES ACT LIABILITY </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the registrant pursuant to the foregoing provisions, the registrant has been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. </font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:left;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:left;border-top:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:center;border-bottom:1pt none #D9D9D9 ;color:#0000FF;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			&nbsp;
		</p>
		<p style="margin:13pt 0pt 0pt;background-color: #FFFFFF;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">28</font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font><font style="display:inline;"></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:13pt 0pt 0pt;background-color: #FFFFFF;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-size:10pt;"><img src="glyc20160301xs3001.jpg" style="width: 3.072917in; height: 0.6041667in" alt="Picture 4"></font>
		</p>
		<p style="margin:13pt 0pt 0pt;background-color: #FFFFFF;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">$</font><font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">19</font><font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">,000,000</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">&nbsp;</font><font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">Common Stock</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="center"></hr></div>
		<p style="margin:24pt 0pt 0pt;background-color: #FFFFFF;text-align:center;border-top:1pt none #D9D9D9 ;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">Prospectus</font><font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;"> Supplement</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:0pt;text-align:center;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="margin-bottom:6pt;"><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="center"></hr></div>
		<p style="margin:24pt 0pt 0pt;background-color: #FFFFFF;text-align:center;border-bottom:1pt none #D9D9D9 ;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:24pt 0pt 0pt;background-color: #FFFFFF;text-align:center;border-top:1pt none #D9D9D9 ;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">Cowen and Company</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:0pt;text-align:center;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="margin-bottom:6pt;"><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="center"></hr></div>
		<p style="margin:24pt 0pt 0pt;background-color: #FFFFFF;text-align:center;border-bottom:1pt none #D9D9D9 ;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:24pt 0pt 0pt;background-color: #FFFFFF;text-align:center;border-top:1pt none #D9D9D9 ;color:#000000;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">March </font><font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">1</font><font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">, 2016</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;line-height:10pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">&nbsp;</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>glyc20160301xs3001.jpg
<TEXT>
begin 644 glyc20160301xs3001.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 9      !_^$ 2D5X:68
M $U- "H    (  ,!&@ %     0   #(!&P %     0   #H!*  #     0 "
M         &     !    8     $  /_M"+I0:&]T;W-H;W @,RXP #A"24T#
M[0      $ !@     0 ! &     !  $X0DE-! T       0    >.$))3009
M       $    'CA"24T#\P      "0           0 X0DE-! H       $
M #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      &T    &              !'   !:@    8 9P S
M #4 <0 V #@    !                          $              6H
M  !'                                             #A"24T$$0
M     0$ .$))3004       $     CA"24T$#      &'0    $   !P
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
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MZJ3>W<>-T"?&-87RLDDI^JDE\JI)*?_9 #A"24T$(0      50    $!
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M P,# P,# P,# P/_P  1" !' 6H# 1$  A$! Q$!_\0 '0 !  $% 0$!
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ME.*4XI7_TL?>,S]%;Y,_]0'C:_.HIW*\XI_FAQO^W\?_ 'N&K3>X3^0W-O\
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M,W?]/I+F[46\R,?#] ]S+&Q\/H()(!8RA\@_Z2W /]PO^)LIRU_M]_IJW_\
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M._Y+;N63]GO\V;G]D7'ZRWK*/\2;^GFR_B.S_47E9=\8'^1G!_\ >7_B_?\
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M_NG"W6/S=NW;)!<1M%(I^:N 2#XJPU5AU4D$&JASTZ\.G%*^;()":LT)1JI
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MXY]K'1Z+=FW]P\<**G["!WJ',8>IC"(\;_(7^5NY;_)WTUS?2:=TDKM)(W:
MJ]SN2QT4!1J>@  Z 5VXG#XC 8^WQ."Q5M98J+N[(8(DAB3N8NW9'&JHO<[,
M[: :LQ8]235#BL<8\@I][:X.ATR&M,D=ZI(V6*J\''3[]227]U(G>S+1BC(N
MCR#G[1<3J&%4_P!8W4?CS[KK<>X;_'PXF^SU[-BXPH2%YY7B4(.U L;,47L7
MHN@':.@T%>3C]D[-Q.7NMPXK:6,ML_.7,ES%:P1W$AE;ND+S)&)',C?4Y9CW
MMU;4U][30Z->4V:5VIE3N*4<=92/2M-=A[ FP4<E3*X.S)+,W96IW!42 <2
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MG0E>Y"K:$@:C70Z#X5]^<V]@-S60QVY,'9Y#'APXBN88YX^]00K]DJNO< 2
MVFH!.AZFO3 U^!JT4U@:Q"1%<@V'K^QAH&-91$4S]TY6>.?:QT>BW9M_</'"
MBI^P@=ZAS&'J8PB/7?Y"_P K=RW^3OIKF^DT[I)7:21NT!5[G<ECHH"C4]
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G.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
